

## WEST Search History





DATE: Monday, July 16, 2007

Hide?	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT; PLUR=YES; OP=ADJ</i>	
<input type="checkbox"/>	L24	7041286.pn.	1
<input type="checkbox"/>	L23	L22 and (@AD<20031230 or @RLAD<20031230 or @PRAD<20031230)	39
<input type="checkbox"/>	L22	L18 and (bodybuilding or anabolic)	47
<input type="checkbox"/>	L21	L20 and lycopene	4
<input type="checkbox"/>	L20	L19 and (@AD<20031230 or @RLAD<20031230 or @PRAD<20031230)	106
<input type="checkbox"/>	L19	L18 and (bodybuilding or anabolic or testosterone)	127
<input type="checkbox"/>	L18	colostrum	1726
<input type="checkbox"/>	L17	L11 and (bodybuilding or anabolic)	15
<input type="checkbox"/>	L16	L11 and (bodybuilding or (weight loss))	37
<input type="checkbox"/>	L15	L11 and (bodybuilding or (weight loss) or muscle)	130
<input type="checkbox"/>	L14	L12 and colostrum	5
<input type="checkbox"/>	L13	L12 and colustrum	1
<input type="checkbox"/>	L12	L11 and (bodybuilding or (weight loss) or muscle or anabolic)	132
<input type="checkbox"/>	L11	bee pollen	292
<input type="checkbox"/>	L10	20040071825.did.	1
<input type="checkbox"/>	L9	20020002198.did.	1
<input type="checkbox"/>	L8	6368617.did.	1
<input type="checkbox"/>	L7	20040005368.did.	1
<input type="checkbox"/>	L6	L-arginine-2-pyrrolidone-5-carboxylate	1
<input type="checkbox"/>	L5	L-arginine-2-pyrrolidine-5-carboxylate	0
<input type="checkbox"/>	L4	6368617.did.	1
<input type="checkbox"/>	L3	6784209.did.	1
<input type="checkbox"/>	L2	20030108537.did.	1
<input type="checkbox"/>	L1	20070116743.did.	1

END OF SEARCH HISTORY

-----

L22 FILE 'HCAPLUS' ENTERED AT 13:17:19 ON 16 JUL 2007  
9 S L5 (5A) L18

FILE 'STNGUIDE' ENTERED AT 13:17:21 ON 16 JUL 2007

L23 FILE 'HCAPLUS' ENTERED AT 13:17:58 ON 16 JUL 2007  
1 S L22 AND (PY<1997 OR AY<1997 OR PRY<1997)

L24 FILE 'STNGUIDE' ENTERED AT 13:20:52 ON 16 JUL 2007  
0 S L5 AND ((ALLREGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT

L25 0 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:08 ON 16 JUL 2007

L26 FILE 'HCAPLUS' ENTERED AT 13:21:20 ON 16 JUL 2007  
939 S L5 AND ((ALLREGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT

L27 695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:25 ON 16 JUL 2007

L28 FILE 'HCAPLUS' ENTERED AT 13:21:38 ON 16 JUL 2007  
1081 S L5 AND ((ALLERGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT

L29 695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:42 ON 16 JUL 2007

L30 FILE 'HCAPLUS' ENTERED AT 13:22:12 ON 16 JUL 2007  
163 S L5 (6A) ((ALLERGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANTI

L31 695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:22:17 ON 16 JUL 2007

L32 FILE 'HCAPLUS' ENTERED AT 13:22:37 ON 16 JUL 2007  
103 S L30 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'REGISTRY' ENTERED AT 14:08:07 ON 16 JUL 2007  
EXP L-ARGININE-2-PYRROLIDONE-5-CARBOXYLATE/CN

L33 1 S MALTODEXTRIN/CN

L34 2 S LYSINE/CN

FILE 'STNGUIDE' ENTERED AT 14:09:27 ON 16 JUL 2007

FILE 'REGISTRY' ENTERED AT 14:13:35 ON 16 JUL 2007  
EXP ACETYL-L-CARNITINE/CN

L35 1 S E3

FILE 'STNGUIDE' ENTERED AT 14:14:01 ON 16 JUL 2007

L36 FILE 'HCAPLUS' ENTERED AT 14:15:48 ON 16 JUL 2007  
2 S L-ARGININE-2-PYRROLIDONE-5-CARBOXYLATE

L37 1041 S L35

L38 55755 S L33 OR L34

L39 1 S L36 AND L37 AND L38

L40 94029 S CORTISOL OR (HUMAN GROWTH HORMONE) OR EXERCISE OR BODYBUILDIN

FILE 'HCAPLUS' ENTERED AT 14:17:07 ON 16 JUL 2007

L41 1 S L36 AND L37

L42 75 S L37 AND L40

FILE 'STNGUIDE' ENTERED AT 14:17:10 ON 16 JUL 2007

L43 FILE 'HCAPLUS' ENTERED AT 14:17:36 ON 16 JUL 2007  
54 S L42 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'HCAPLUS' ENTERED AT 15:13:35 ON 16 JUL 2007

L44 268 S BEE(W) POLLEN  
L45 15 S COLUSTRUM  
L46 5582 S LYCOPENE  
L47 1 S MACUNA PRURIENS  
L48 433 S GLYCERYLPHOSPHORYLCHOLINE  
L49 57749 S (GROWTH HORMONE) OR ANABOLIC OR BODYBUILDING

FILE 'STNGUIDE' ENTERED AT 15:13:41 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:14:35 ON 16 JUL 2007

L50 3 S L44 AND L49  
L51 0 S L45 AND L49  
L52 14 S L46 AND L49  
L53 5 S L48 AND L49

FILE 'HCAPLUS' ENTERED AT 15:18:13 ON 16 JUL 2007

L54 4612 S MALTODEXTRIN  
L55 5 S L53 AND L49

FILE 'STNGUIDE' ENTERED AT 15:18:32 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:19:12 ON 16 JUL 2007

L56 15 S L54 AND L49

FILE 'STNGUIDE' ENTERED AT 15:19:14 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:19:31 ON 16 JUL 2007

L57 9 S L56 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'HCAPLUS' ENTERED AT 15:49:59 ON 16 JUL 2007

L58 487 S MUCUNA  
L59 554 S BOVINE COLOSTRUM  
L60 13977 S 58 AND 49  
L61 12339 S 59 AND 49  
L62 1104683 S 60 AND (PY<2004 OR AY<2004 OR PRY<2004)  
L63 157831 S 61 AND (PY<2004 OR AY<2004 OR PRY<2004)

FILE 'STNGUIDE' ENTERED AT 15:50:10 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:50:40 ON 16 JUL 2007

L64 3 S L58 AND L49  
L65 9 S L59 AND L49  
L66 3 S L64 AND (PY<2004 OR AY<2004 OR PRY<2004)  
L67 7 S L65 AND (PY<2004 OR AY<2004 OR PRY<2004)


=> exp L-arginine-2-pyrrolidone-5-carboxylate/cn`  
 E1 1 L-ARGININE-2-D/CN  
 E2 1 L-ARGININE-2-D, MONOHYDROCHLORIDE/CN  
 E3 0 --> L-ARGININE-2-PYRROLIDONE-5-CARBOXYLATE/CN  
 E4 1 L-ARGININE-3,4,5,5-T4/CN  
 E5 1 L-ARGININE-3,4-T2/CN  
 E6 1 L-ARGININE-4'-PROPOXYAZOBENZENE-4-SULFONATE/CN  
 E7 1 L-ARGININE-4,4-D2/CN  
 E8 1 L-ARGININE-4,5-T2/CN  
 E9 1 L-ARGININE-4-D, ERYTHRO-/CN  
 E10 1 L-ARGININE-4-D, THREO-/CN  
 E11 1 L-ARGININE-4-NITROANILIDE HYDROCHLORIDE/CN  
 E12 1 L-ARGININE-5,5-D2, 3-HYDROXY-, ERYTHRO-/CN

=> s maltodextrin/cn  
 L33 1 MALTODEXTRIN/CN

=> s lysine/cn  
 L34 2 LYSINE/CN

=> d l34 scan

L34 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN Lysine  
 MF C6 H14 N2 O2  
 CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L34 2 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN  
 IN L-Lysine  
 MF C6 H14 N2 O2  
 CI COM

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> file stnguide  
 COST IN U.S. DOLLARS

SINCE FILE

TOTAL

FULL ESTIMATED COST	ENTRY 10.80	SESSION 235.22
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-27.30

FILE 'STNGUIDE' ENTERED AT 14:09:27 ON 16 JUL 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Jul 13, 2007 (20070713/UP) ..

=> file registry		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.42	235.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-27.30

FILE 'REGISTRY' ENTERED AT 14:13:35 ON 16 JUL 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUL 2007 HIGHEST RN 942400-66-0  
 DICTIONARY FILE UPDATES: 15 JUL 2007 HIGHEST RN 942400-66-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

```
=> exp acetyl-L-carnitine/cn
E1      1      ACETYL-L-ALANYLGLYCYLGLYCINE METHYL ESTER/CN
E2      1      ACETYL-L-ASPARTIC ACID/CN
E3      1  --> ACETYL-L-CARNITINE/CN
E4      1      ACETYL-L-CARNITINE ACID PHOSPHATE/CN
E5      1      ACETYL-L-CARNITINE ACID SULFATE/CN
E6      1      ACETYL-L-CARNITINE GLUCOSE PHOSPHATE/CN
E7      1      ACETYL-L-CARNITINE GLYCEROPHOSPHATE/CN
E8      1      ACETYL-L-CARNITINE LACTATE/CN
E9      1      ACETYL-L-CARNITINE MAGNESIUM CITRATE/CN
E10     1      ACETYL-L-CARNITINE METHANESULFONATE/CN
E11     1      ACETYL-L-CARNITINE OROTATE/CN
E12     1      ACETYL-L-CARNITINE TRICHLOROACETATE/CN
```

```
=> s E3
L35      1 ACETYL-L-CARNITINE/CN
```

=> file stnguide  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
5.40	241.04

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-27.30

CA SUBSCRIBER PRICE

FILE 'STNGUIDE' ENTERED AT 14:14:01 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> file hcaplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.18	241.22

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-27.30

CA SUBSCRIBER PRICE

FILE 'HCAPLUS' ENTERED AT 14:15:48 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4  
FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s L-arginine-2-pyrrolidone-5-carboxylate

1578653 L  
116741 ARGININE  
9219861 2  
23653 PYRROLIDONE  
6432781 5  
73049 CARBOXYLATE

L36 2 L-ARGININE-2-PYRROLIDONE-5-CARBOXYLATE  
(L (W) ARGININE (W) 2 (W) PYRROLIDONE (W) 5 (W) CARBOXYLATE)

=> s 135

L37 1041 L35

=> s 133 or 134

4124 L33  
51721 L34  
L38 55755 L33 OR L34

=> s 136 and 137 and 138

L39 1 L36 AND L37 AND L38

=> s cortisol or (human growth hormone) or exercise or bodybuilding or (weight loss) or (burn(3a) fat)

37004 CORTISOL  
1809911 HUMAN  
1359998 GROWTH  
293189 HORMONE  
8020 HUMAN GROWTH HORMONE  
(HUMAN (W) GROWTH (W) HORMONE)  
46773 EXERCISE  
44 BODYBUILDING  
143414 WEIGHT  
629625 LOSS  
4207 WEIGHT LOSS  
(WEIGHT (W) LOSS)  
31513 BURN  
190708 FAT  
44 BURN (3A) FAT  
L40 94029 CORTISOL OR (HUMAN GROWTH HORMONE) OR EXERCISE OR BODYBUILDING  
OR (WEIGHT LOSS) OR (BURN (3A) FAT)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.60	243.82
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-27.30

FILE 'STNGUIDE' ENTERED AT 14:15:54 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> d 139 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L39 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Nutritional supplement for enhancing the production and effect of natural human growth hormone  
AB A nutritional supplement for enhancing the production and effect of natural human growth hormone includes: L-arginine-2-pyrrolidone-5-carboxylate in an amount of about 500 mg to about 10 g; L-lysine-HCl in an amount of about 500 mg to about 10 g; and a cortisol suppressant including at least one of acetyl-L-carnitine in an amount of about 1 g to about 10 g and maltodextrin in an amount of about 1 g to about 10 g.

AN 2005:570531 HCAPLUS <<LOGINID::20070716>>  
 DN 143:83512  
 TI Nutritional supplement for enhancing the production and effect of natural  
 human growth hormone  
 IN Nerenberg, Arnold P.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 7 pp.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2005143343	A1	20050630	US 2003-748615	20031230
PRAI	US 2003-748615		20031230		

=> file hcaplus  
 COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
0.12	249.43

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE ENTRY	TOTAL SESSION
0.00	-28.08

CA SUBSCRIBER PRICE

FILE 'HCAPLUS' ENTERED AT 14:17:07 ON 16 JUL 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4  
 FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l36 and l37

L41 1 L36 AND L37

=> s l37 and l40

L42 75 L37 AND L40

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE ENTRY	TOTAL SESSION
2.60	252.03

FULL ESTIMATED COST



DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-28.08

FILE 'STNGUIDE' ENTERED AT 14:17:10 ON 16 JUL 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> file hcaplus  
 COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.06	252.09

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-28.08

FILE 'HCAPLUS' ENTERED AT 14:17:36 ON 16 JUL 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4  
 FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l42 and (PY<2003 or AY<2003 or PRY<2003)

22885849 PY<2003  
 4448261 AY<2003  
 3926713 PRY<2003

L43 54 L42 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	2.60	254.69

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-28.08

FILE 'STNGUIDE' ENTERED AT 14:17:39 ON 16 JUL 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> d 143 1-54 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

- L43 ANSWER 1 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose.
- L43 ANSWER 2 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Therapeutic formulations for the treatment of  $\beta$ -amyloid-related diseases
- L43 ANSWER 3 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Mental agility lozenge, edible strip, food or drink
- L43 ANSWER 4 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Food supplement containing amino acids and nitric oxide producers for increasing lean mass and strength.
- L43 ANSWER 5 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Therapeutic formulations for the treatment of beta-amyloid related diseases containing two active ingredients
- L43 ANSWER 6 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Method for enhancing the natural reward system for exercise
- L43 ANSWER 7 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
- L43 ANSWER 8 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Compositions of flavonoids and synergists for use as cytoprotectants and methods of making and using them
- L43 ANSWER 9 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Composition and method for normalizing impaired or deteriorating neurological function
- L43 ANSWER 10 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Carbohydrate ingestion reduces skeletal muscle acetylcarnitine availability but has no effect on substrate phosphorylation at the onset of exercise in man
- L43 ANSWER 11 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Gender and age differences in plasma carnitine, muscle strength, and exercise tolerance in haemodialysis patients
- L43 ANSWER 12 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Use of carnitine for increasing testosterone
- L43 ANSWER 13 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Substrate utilization during graded aerobic exercise in rainbow trout
- L43 ANSWER 14 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Skeletal muscle metabolism is unaffected by DCA infusion and hyperoxia after onset of intense aerobic exercise

L43 ANSWER 15 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Exercise with low muscle glycogen augments TCA cycle anaplerosis but impairs oxidative energy provision in humans

L43 ANSWER 16 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Dietary supplement for promoting healthy hormonal balance

L43 ANSWER 17 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Glycogen phosphorylase and pyruvate dehydrogenase transformation in white muscle of trout during high-intensity exercise

L43 ANSWER 18 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI L-Carnitine L-tartrate supplementation favorably affects markers of recovery from exercise stress

L43 ANSWER 19 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Lipid oxidation fuels recovery from exhaustive exercise in white muscle of rainbow trout

L43 ANSWER 20 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Dietary supplement containing two bioactive components acting synergistically to elevate growth hormone release in vertebrates

L43 ANSWER 21 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Effects of acetate infusion and hyperoxia on muscle substrate phosphorylation after onset of moderate exercise

L43 ANSWER 22 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI The effects of increasing exercise intensity on muscle fuel utilisation in humans

L43 ANSWER 23 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Effect of propionyl-L-carnitine on exercise performance in peripheral arterial disease

L43 ANSWER 24 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise

L43 ANSWER 25 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Increases in VO<sub>2</sub>max and metabolic markers of fat oxidation by caffeine, carnitine, and choline supplementation in rats

L43 ANSWER 26 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Carbohydrate ingestion prior to exercise augments the exercise-induced activation of the pyruvate dehydrogenase complex in human skeletal muscle

L43 ANSWER 27 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Pyruvate overrides inhibition of PDH during exercise after a low-carbohydrate diet

L43 ANSWER 28 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Normal carnitine levels in patients with chronic fatigue syndrome

L43 ANSWER 29 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Regulation of glycogen phosphorylase and PDH during exercise in human skeletal muscle during hypoxia

L43 ANSWER 30 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Sensitivity of CPT I to malonyl-CoA in trained and untrained human skeletal muscle

L43 ANSWER 31 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Non-invasive observation of acetyl-group buffering by 1H-MR spectroscopy in exercising human muscle

L43 ANSWER 32 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Skeletal muscle metabolism during high-intensity sprint exercise is unaffected by dichloroacetate or acetate infusion

L43 ANSWER 33 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Regulation of skeletal muscle glycogen phosphorylase and PDH during maximal intermittent exercise

L43 ANSWER 34 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effect of induced metabolic acidosis on human skeletal muscle metabolism during exercise

L43 ANSWER 35 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Composition comprising L-carnitine or an alkanoyl L-carnitine and NADH and/or NADPH for treatment of fatigue or parkinsonism

L43 ANSWER 36 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Compositions containing ketanserin and L-carnitine or an alkanoyl L-carnitine for the treatment of chronic regional pain syndrome (CRPS)

L43 ANSWER 37 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Cardiovascular and neuroendocrine responses to exercise in hypoxia during impaired neural feedback from muscle

L43 ANSWER 38 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effects of dichloroacetate infusion on human skeletal muscle metabolism at the onset of exercise

L43 ANSWER 39 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Pyruvate dehydrogenase activation in inactive muscle during and after maximal exercise in men

L43 ANSWER 40 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI The importance of pyruvate availability to PDC activation and anaplerosis in human skeletal muscle

L43 ANSWER 41 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Nutritional composition for improvements in cell energetics

L43 ANSWER 42 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals

L43 ANSWER 43 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Nutritional supplement for increased muscle size and strength for body builders

L43 ANSWER 44 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Regulation of skeletal muscle glycogen phosphorylase and PDH at varying exercise power outputs

L43 ANSWER 45 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Skeletal muscle malonyl-CoA content at the onset of exercise at varying power outputs in humans

L43 ANSWER 46 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effects of increased fat availability on fat-carbohydrate interaction during prolonged exercise in men

L43 ANSWER 47 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Muscle acetyl group availability is a major determinant of oxygen deficit in humans during submaximal exercise

L43 ANSWER 48 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Substrate availability limits human skeletal muscle oxidative ATP regeneration at the onset of ischemic exercise

L43 ANSWER 49 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Acetyl-L-carnitine in Alzheimer disease: A short-term study on CSF neurotransmitters and neuropeptides

L43 ANSWER 50 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effects of carnitine derivatives on the fitness of pretrained animals

L43 ANSWER 51 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Pituitary-adrenal function and cognitive performance in demented patients on acetyl-L-carnitine treatment

L43 ANSWER 52 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Aging modifies the hormonal responses in women

L43 ANSWER 53 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Acetyl-L-carnitine acutely administered raises  $\beta$ -endorphin and cortisol plasma levels in humans

L43 ANSWER 54 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Acetyl-L-carnitine normalizes pituitary-adrenocortical hyperactivity in pathological aging brain

=> d 143 1 3 4 6 7 12 16 20 21 24 25 41 42 43 49 ti abs bib  
 YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L43 ANSWER 1 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose.  
 AB A health food/dietary supplement is disclosed suitable for enhancing muscular energy metabolism, comprising as its characterizing active ingredients an alkanoyl L-carnitine and ribose.  
 AN 2007:560639 HCAPLUS <<LOGINID::20070716>>  
 DN 146:481114  
 TI Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose.  
 IN Pietro, Pola  
 PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy  
 SO U.S. Pat. Appl. Publ., 6pp., Cont.-in-part of U.S. Ser. No. 48,590.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2007116743	A1	20070524	US 2006-604390	20061127 <--
	IT 2000RM0323	A1	20011214	IT 2000-RM323	20000614 <--
	WO 2001095915	A1	20011220	WO 2001-IT283	20010601 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 2003108537 A1 20030612 US 2002-48590 20020201 <--  
PRAI IT 2000-RM323 A 20000614 <--  
WO 2001-IT283 W 20010601 <--  
US 2002-48590 A2 20020201 <--

L43 ANSWER 3 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Mental agility lozenge, edible strip, food or drink

AB A mental agility composition is composed of at least one agent which promotes synthesis of ATP and/or creatine phosphate in the body; at least one antioxidant for scavenging free radicals in at least one pathway in the body; at least one agent for normalizing or maintaining membrane function and structure in the body; at least one agent for normalizing or maintaining normal neurotransmitter function in the body; at least one agent for down-regulating cortisol action; and at least one agent for suppressing activation of apoptotic pathways in the body. The composition may further contain one or more of at least one agent for suppressing inflammation in the body; at least one agent for normalizing or maintaining vascular wall function and structure in the body; at least one agent for normalizing or maintaining function of nerve growth factors and/or neurotropic factors in the body; at least one agent for suppressing toxic metal ionic effects; at least one agent for normalizing or maintaining Me metabolism in the body; at least one agent for normalizing or maintaining metabolism of insulin and glucose in the body; and at least one agent for up-regulating activity of heat shock proteins in the body. The composition is administered in the form of a breath-care strip, mint or lozenge, or a food or beverage product.

AN 2006:53908 HCAPLUS <<LOGINID::20070716>>

DN 144:135267

TI Mental agility lozenge, edible strip, food or drink

IN McCleary, Edward Larry

PA USA

SO U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. Ser. No. 49,244.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 12

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2006014773	A1	20060119	US 2005-223719	20050909 <--
	US 2002182196	A1	20021205	US 2001-837562	20010419 <--
	US 6964969	B2	20051115		
	US 2004043013	A1	20040304	US 2003-462958	20030617 <--
	US 2005025812	A1	20050203	US 2003-616674	20030710
	US 2005002992	A1	20050106	US 2004-890067	20040712
	US 2006110477	A1	20060525	US 2005-49237	20050202
	US 2006110478	A1	20060525	US 2005-49244	20050202
	WO 2006057893	A2	20060601	WO 2005-US41765	20051117
	WO 2006057893	A3	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2001-837562 A2 20010419 <--  
US 2003-462958 A2 20030617

US 2003-616674	A2	20030710	
US 2003-520466P	P	20031114	
US 2004-536286P	P	20040113	
US 2004-890067	A2	20040712	
US 2004-630529P	P	20041122	
US 2005-49244	A2	20050202	
US 2000-749584	A2	20001228	<--
US 2005-49237	A	20050202	

L43 ANSWER 4 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Food supplement containing amino acids and nitric oxide producers for increasing lean mass and strength.

AB Food supplement compns. and their methods of use in increasing lean mass and/or muscle size and/or strength in individuals, particularly, athletes are described. The food supplements described comprise a substance which increases nitric oxide production in the body, and, a source of amino acids. Other food supplements described comprise a substance which can enhance and/or mimic insulin activity, and a source of amino acids. The food supplement compns. described are suitable for supplementing the diet of an athlete and particularly for enhancing an athlete's muscle size or strength.

AN 2004:716897 HCAPLUS <<LOGINID::20070716>>

DN 141:224392

TI Food supplement containing amino acids and nitric oxide producers for increasing lean mass and strength.

IN Gardiner, Paul T.; Woodgate, Derek E.; Gilbert, Mark S.; Thoburn, Robert W.

PA Muscletech Research and Development Inc., Can.

SO U.S., 7 pp., Cont.-in-part of U.S. Ser. No. 420,439, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6784209	B1	20040831	US 2000-482688	20000113 <--
	CA 2388733	A1	20010426	CA 2000-2388733	20001018 <--
	WO 2001028356	A2	20010426	WO 2000-CA1207	20001018 <--
	WO 2001028356	A3	20011101		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1221865	A2	20020717	EP 2000-969121	20001018 <--
	EP 1221865	B1	20070103		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003511094	T	20030325	JP 2001-530960	20001018 <--
	NZ 518685	A	20040430	NZ 2000-518685	20001018 <--
	AU 784752	B2	20060608	AU 2000-78948	20001018 <--
	AT 349909	T	20070115	AT 2000-969121	20001018 <--
	MX 2002PA03861	A	20030714	MX 2002-PA3861	20020417 <--
	US 2004175442	A1	20040909	US 2004-799028	20040311 <--
	US 2004175443	A1	20040909	US 2004-799038	20040311 <--
	US 2004234626	A1	20041125	US 2004-874526	20040622 <--
PRAI	US 1999-420439	B2	19991018	<--	
	US 2000-482688	A	20000113	<--	
	WO 2000-CA1207	W	20001018	<--	

RE.CNT 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 6 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Method for enhancing the natural reward system for exercise

AB Methods of enhancing and prolonging the natural reward system for exercise by administering one or more opiate destruction-inhibitors alone or in combination with one or more neurotransmitter precursors. When people exercise, they can experience a "runner's high" or a state of euphoria, which has been found to be based on natural opioids. By enhancing and prolonging the "runner's high," incentive to exercise and to continue exercising will be increased. Further methods include the addition of any of a number of additives, such as those conventionally used for weight loss and appetite suppression.

AN 2004:495676 HCAPLUS &lt;&lt;LOGINID::20070716&gt;&gt;

DN 141:47382

TI Method for enhancing the natural reward system for exercise

IN Halevie-Goldman, Brian D.

PA Fast Balance, Inc., USA

SO U.S. Pat. Appl. Publ., 9 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004116351	A1	20040617	US 2003-730627	20031208 <--
PRAI	US 2002-431255P	P	20021206	<--	
	US 2003-468041P	P	20030505		

L43 ANSWER 7 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite

AB Formulations and methods for enhancing lipolysis and the suppression of appetite are presented. Currently the preferred embodiment has these formulations as two sep. compns. because of taste considerations (the combined taste, currently, is disagreeable). However, it is known that the two sep. compns. can be combined into a single delivery systems, such as a drink, bar, gel or other nutritional delivery system known in the arts. The two sep. compns. are: (1) compns. comprising substances that enhance oxygen uptake, and (2) a protein supplement composition comprising substances that regulate blood sugar. The overall purpose of this invention is to induce weight loss in as short of time as possible with the least amount of discomfort. A claimed composition for weight loss comprises:

(1) a first composition containing at least one substance that enhance oxygen uptake comprising caffeine, theophylline, Gingko-A, L-pyroglutamate, xanthinol nicotinate, N-acetyl-L-carnitine, choline bitartrate, DMAE, Mg glycinate, K aspartate, Cr arginate, L-phenylalanine, and (2) a second composition containing

a protein supplement comprising at least one protein source and at least one substance that regulates blood sugar comprising: soy protein, inulin, L-methionine, MCT oil, vanilla flavoring, sucralose, CM-cellulose, carrageenan, Mg phosphate, Cr arginate, Cr chelidamate, glycine, vanadyl sulfate, and Mn gluconate.

AN 2004:18741 HCAPLUS &lt;&lt;LOGINID::20070716&gt;&gt;

DN 140:82253

TI Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite

IN Mann, Morris; Mann, Maria A.

PA USA

SO U.S. Pat. Appl. Publ., 22 pp.



CODEN: USXXCO

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004005368	A1	20040108	US 2002-187668	20020701 <--
PRAI	US 2002-187668		20020701	<--	

L43 ANSWER 12 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Use of carnitine for increasing testosterone

AB Use of carnitine or alkanoyl-carnitine administration to a human for increasing serum levels of testosterone.

AN 2002:695770 HCAPLUS <<LOGINID::20070716>>

DN 137:210998

TI Use of carnitine for increasing testosterone

IN Schaffhauser, Andrea; Gaynor, Paula

PA Lonza A.-G., Switz.

SO PCT Int. Appl., 8 pp.

CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002069956	A2	20020912	WO 2002-EP464	20020118 <--
	WO 2002069956	A3	20021107		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002257572	A1	20020919	AU 2002-257572	20020118 <--
PRAI	EP 2001-101355	A	20010122	<--	
	WO 2002-EP464	W	20020118	<--	

L43 ANSWER 16 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Dietary supplement for promoting healthy hormonal balance

AB A dietary supplement for promoting healthy hormonal balance in adult human subjects, and especially in elderly subjects, comprises a secretagogue for stimulating the release of human growth

hormone (hGH) by the pituitary, and the conversion by hGH to insulin-like growth factor 1 (IGF-1), in combination with 7-keto-dehydroepiandrosterone (7-keto DHEA). The dietary supplement also includes other interacting ingredients for delivering antioxidants for retarding damage at the cellular level caused by the presence of free radicals, and natural herbs for promoting physiol. health. For example, an essentially dry powder constituting a dietary supplement of this invention, to be dissolved in water to provide a daily serving, contained 7-keto-DHEA 25 mg, Symbiotropin 1000 mg, lecithin 200 mg, maltodextrin 7.227 mg, citric acid 640 mg, dipotassium phosphate 25 mg, potassium citrate 25 mg, probiotic blend 100 mg, fruco-oligosaccharides 400 mg, S-adenosyl-L-methionine 5 mg, acetyl-L-carnitine 100 mg, omega-3 fatty acids (Dry n-3) 125 mg, trimethylglycine 100 mg, coenzyme Q10 7.5 mg, resveratrol (Protykin) 10 mg,  $\alpha$ -lipoic acid 50 mg, L-glutathione 30 mg, N-acetylcysteine 200 mg, and flavoring agents 300 mg.

AN 2002:271056 HCAPLUS <<LOGINID::20070716>>

DN 136:299719

TI Dietary supplement for promoting healthy hormonal balance

IN Hastings, Carl W.; Barnes, David J.; Daley, Christine A.

PA Reliv' International, Inc., USA  
SO U.S., 5 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6368617	B1	20020409	US 2001-858047	20010515 <--
PRAI	US 2001-858047		20010515	<--	

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 20 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Dietary supplement containing two bioactive components acting synergistically to elevate growth hormone release in vertebrates  
AB Growth hormone (GH) release in vertebrates may be augmented by an oral dietary supplement composed of acetyl-l-carnitine and l-ornithine acting in synergy. Augmentation is most efficacious by ingestion at night sleep after a short fast, but may be used during the day. Human dosages in subgram levels allow precise and reliable control of the level of augmented GH release over greater than one order of magnitude range above normal levels. This method can: return aging declined GH release to young adult levels, cause rapid fat loss without protein loss or extreme hunger, enable prolonged wakeful alertness and strength during emergencies, promote anabolic function in catabolic disease or trauma, and rapidly mature domestic animals.

AN 2002:11107 HCAPLUS <<LOGINID::20070716>>  
DN 136:48481

TI Dietary supplement containing two bioactive components acting synergistically to elevate growth hormone release in vertebrates

IN Parr, Tyler B.

PA USA

SO U.S. Pat. Appl. Publ., 8 pp.  
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002002198	A1	20020103	US 2001-835501	20010416 <--
PRAI	US 2000-197470P	P	20000417	<--	

L43 ANSWER 21 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Effects of acetate infusion and hyperoxia on muscle substrate phosphorylation after onset of moderate exercise

AB This study investigated whether increased muscle acetylcarnitine provision (acetate infusion) or hyperoxia (100% O<sub>2</sub>) would increase the rate of oxidative phosphorylation and reduce the reliance on muscle substrate phosphorylation after the onset of moderate exercise. Eight subjects completed three randomized trials, each separated by 1 wk: (1) saline infusion for 1 h before exercise, while breathing room air for 20 min before exercise and during 120 s of cycling at 65% maximal exercise (VO<sub>2</sub> max) (CON), (2) saline infusion with 4 mmol/kg body wt sodium acetate, while breathing room air before and during exercise (ACE), and (3) saline infusion and breathing 100% O<sub>2</sub> before and during exercise (HYP). Muscle biopsies were sampled at rest and after 30 and 120 s of exercise. ACE increased muscle acetyl-CoA and acetylcarnitine contents at rest vs. CON and HYP [22.9 ± 2.8 vs. 8.9 ± 2.4 and 10.5 ± 1.8 μmol/kg dry muscle (dm); 11.0 ± 1.2 vs. 3.5 ± 1.3 and 4.0 ± 1.2 mmol/kg dm]. Acetate had no effect on resting pyruvate dehydrogenase activity in the active form (PDHa) among CON, ACE, and HYP. During exercise, acetyl-CoA and acetylcarnitine were unchanged in ACE but increased over

time in the CON and HYP trials, and PDHa increased similarly in all trials. Muscle phosphocreatine use, lactate accumulation, and substrate phosphorylation energy provision after 30 or 120 s of exercise were similar in all trials. In summary, increased acetylcarnitine availability did not accelerate the rate of oxidative phosphorylation at the onset of exercise, suggesting that this is not a site of extra substrate. Hyperoxia had no effect on substrate phosphorylation, suggesting that O2 availability does not limit oxidative phosphorylation at the onset of moderate exercise.

AN 2001:936535 HCAPLUS <<LOGINID::20070716>>  
 DN 136:197565  
 TI Effects of acetate infusion and hyperoxia on muscle substrate phosphorylation after onset of moderate exercise  
 AU Evans, Melissa K.; Savasi, Ingrid; Heigenhauser, George J. F.; Spriet, Lawrence L.  
 CS Department of Human Biology and Nutritional Sciences, University of Guelph, Guelph, ON, N1G 2W1, Can.  
 SO American Journal of Physiology (2001), 281(6, Pt. 1), E1144-E1150  
 CODEN: AJPHAP; ISSN: 0002-9513  
 PB American Physiological Society  
 DT Journal  
 LA English

RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 24 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise  
 AB A composition is disclosed suitable for the prevention and/or treatment of muscular energetic deficiencies and states of asthenia for enhancing sport performances and for the treatment of states of heart fatigue, that may take the form of a dietary supplement, dietetic support or of an actual medicine, which comprises as characterizing active ingredients a combination of L-carnitine and/or at least one alkanoyl L-carnitine and creatinol-phosphate.

AN 2001:78170 HCAPLUS <<LOGINID::20070716>>  
 DN 134:130674  
 TI Composition for the prevention of muscle fatigue and skeletal muscle adaptation to strenuous exercise  
 IN Cavazza, Claudio  
 PA Sigma-Tau Healthscience S.p.A., Italy  
 SO PCT Int. Appl., 16 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001006873	A1	20010201	WO 2000-IT308	20000721 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
IT 99RM0467	A1	20010123	IT 1999-RM467	19990723 <--
IT 1306173	B1	20010530		
CA 2377128	A1	20010201	CA 2000-2377128	20000721 <--
EP 1196046	A1	20020417	EP 2000-951844	20000721 <--
EP 1196046	B1	20040407		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

TR 200200179	T2	20020621	TR 2002-179	20000721 <--
HU 200202298	A2	20021028	HU 2002-2298	20000721 <--
AT 263496	T	20040415	AT 2000-951844	20000721 <--
PT 1196046	T	20040831	PT 2000-951844	20000721 <--
ES 2216931	T3	20041101	ES 2000-951844	20000721 <--
AU 778647	B2	20041216	AU 2000-64687	20000721 <--
US 6602512	B1	20030805	US 2002-19546	20020103 <--
NO 2002000337	A	20020322	NO 2002-337	20020122 <--
MX 2002PA00780	A	20020820	MX 2002-PA780	20020122 <--
PRAI IT 1999-RM467	A	19990723	<--	
WO 2000-IT308	W	20000721	<--	

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 25 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Increases in VO2max and metabolic markers of fat oxidation by caffeine, carnitine, and choline supplementation in rats

AB We have previously shown that the combination of caffeine, carnitine, and choline supplementation decreased body fat and serum leptin concentration in rats

and was attributed to increased fat utilization for energy. As a result, it was hypothesized that the supplements may augment exercise performance including physiolo. and biochem. indexes. Twenty 7-wk-old male Sprague-Dawley rats were given free access to a nonpurified diet with or without supplementation of caffeine, carnitine, and choline at concns. of 0.1, 5, and 11.5 g/kg diet, resp. One half of each dietary group was exercised on a motor-driven treadmill for 3 wk and maximal aerobic power (VO2max) was determined on the 18th day of exercise. Rats were killed 24-h postexercise, and blood, regional fat pads, and skeletal muscle were collected. The VO2max was increased ( $P < 0.05$ ) in the supplemented/exercised group; however, the RQ (RQ) was not affected. Postexercised concns. of serum triglycerides were decreased but  $\beta$ -hydroxybutyrate, acylcarnitine, and acetylcarnitine were increased in the supplemented animals. The changes in serum metabolites were complemented by the changes in the muscle and urinary metabolites. The magnitude of increase in urinary acylcarnitines (34-45-fold) is a unique effect of this combination of supplements. Cumulative evidence indicates enhanced  $\beta$ -oxidation of fatty acids without a change in the RQ because acetyl units were excreted in urine as acetylcarnitine and not oxidized to carbon dioxide. For this phenomenon, we propose the term "fatty acid dumping." We conclude that supplementation with caffeine, carnitine, and choline augments exercise performance and promotes fatty acid oxidation as well as disposal in urine.

AN 2000:895925 HCAPLUS <<LOGINID::20070716>>

DN 134:146830

TI Increases in VO2max and metabolic markers of fat oxidation by caffeine, carnitine, and choline supplementation in rats

AU Sachan, D. S.; Hongu, N.

CS Department of Nutrition and Agricultural Experiment Station, University of Tennessee, Knoxville, TN, USA

SO Journal of Nutritional Biochemistry (2000), 11(10), 521-526

CODEN: JNBIEL; ISSN: 0955-2863

PB Elsevier Science Inc.

DT Journal

LA English

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 41 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Nutritional composition for improvements in cell energetics

AB This invention provides a dietary supplement comprising L-Carnitine (or its functional analogs such as Acetyl-Carnitine or Propionyl-L-Carnitine), Coenzyme Q10 and Taurine useful in the correction of the abnormality in

mitochondrial energetics seen in cardiac failure and certain other diseases. In one preferred embodiment of the invention, a high protein, high calorie nutritional feeding supplement comprising the three aforementioned nutrients together with one or more of Cysteine, Creatine, Vitamin E (RRR-d-alpha-tocopherol), Vitamin C (ascorbic acid), Selenium, and Thiamin is provided.

AN 1998:682101 HCAPLUS <<LOGINID::20070716>>

DN 129:302076

TI Nutritional composition for improvements in cell energetics

IN Sole, Michael J.; Jeejeebhoy, Khursheed N.

PA Can.

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9843617	A2	19981008	WO 1998-CA286	19980325 <--
	WO 9843617	A3	19981217		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	US 6080788	A	20000627	US 1998-2765	19980106 <--
	CA 2284738	A1	19981008	CA 1998-2284738	19980325 <--
	AU 9867153	A	19981022	AU 1998-67153	19980325 <--
	AU 739353	B2	20011011		
	EP 969744	A2	20000112	EP 1998-912176	19980325 <--
	EP 969744	B1	20030521		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	BR 9808088	A	20000308	BR 1998-8088	19980325 <--
	NZ 338026	A	20010928	NZ 1998-338026	19980325 <--
	AT 240661	T	20030615	AT 1998-912176	19980325 <--
	HK 1025018	A1	20040121	HK 2000-104245	20000711 <--
PRAI	US 1997-826234	A	19970327	<--	
	US 1998-2765	A	19980106	<--	
	US 1997-826324	A	19970327	<--	
	WO 1998-CA286	W	19980325	<--	

L43 ANSWER 42 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals

AB A nutritional supplement for facilitating the adaptation of skeletal muscle in individuals undergoing programs of strenuous exercise and counteracting defatigation and weariness in asthenic individuals is disclosed, which comprises a combination of L-carnitine, acetyl L-carnitine and propionyl L-carnitine as basic active ingredients. Optional ingredients comprise isovaleryl L-carnitine, branched-chain amino acids and creatine and/or phosphocreatine.

AN 1998:682080 HCAPLUS <<LOGINID::20070716>>

DN 129:302075

TI Nutritional supplement for facilitating skeletal muscle adaptation to strenuous exercise and counteracting defatigation in asthenic individuals

IN Cavazza, Claudio

PA Sigma-Tau Industrie Farmaceutiche Riunite S.p.A., Italy

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9843499	A2	19981008	WO 1998-IT69	19980327 <--
	WO 9843499	A3	19990107		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2285332	A1	19981008	CA 1998-2285332	19980327 <--
	AU 9867462	A	19981022	AU 1998-67462	19980327 <--
	AU 729412	B2	20010201		
	EP 973415	A2	20000126	EP 1998-912704	19980327 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9807905	A	20000222	BR 1998-7905	19980327 <--
	AT 202675	T	20010715	AT 1998-912704	19980327 <--
	ES 2159179	T3	20010916	ES 1998-912704	19980327 <--
	JP 2001517085	T	20011002	JP 1998-541378	19980327 <--
	PT 973415	T	20011030	PT 1998-912704	19980327 <--
	CN 1074912	B	20011121	CN 1998-803848	19980327 <--
	IL 131857	A	20020421	IL 1998-131857	19980327 <--
	SK 282907	B6	20030109	SK 1999-1349	19980327 <--
	HK 1026124	A1	20020419	HK 2000-105409	20000830 <--
	GR 3036777	T3	20020131	GR 2001-401638	20011003 <--
PRAI	IT 1997-RM185	A	19970401	<--	
	WO 1998-IT69	W	19980327	<--	

L43 ANSWER 43 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Nutritional supplement for increased muscle size and strength for body builders

AB The present invention relates to the method and composition for use of diet supplements by athletes and bodybuilders. A first supplement comprises, the amino acid acetyl-L-carnitine, in conjunction with a series of nutritionally essential branched-chain amino acids, zinc, ornithine  $\alpha$ -ketoglutarate, taurine, in conjunction with two other independently administered supplements; a fat burning agent and a creatine synthesizer. A second diet supplement dosage administered before each meal comprises hydroxycitric acid, ephedra, caffeine, salicin, L-carnitine, and Cr picolinate. A third diet supplement dosage administered before each meal comprises creatine monohydrate and amino acids comprising L-methionine, L-arginine, and L-glycine.

AN 1998:649982 HCAPLUS <<LOGINID::20070716>>

DN 129:281002

TI Nutritional supplement for increased muscle size and strength for body builders

IN Gardiner, Paul T.

PA Can.

SO U.S., 9 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5817329	A	19981006	US 1997-806124	19970228 <--
PRAI	US 1997-806124		19970228	<--	

RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L43 ANSWER 49 OF 54 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Acetyl-L-carnitine in Alzheimer disease: A short-term study on CSF neurotransmitters and neuropeptides  
AB Acetyl-L-carnitine (ALCAR) is a drug currently under investigation for Alzheimer disease (AD) therapy. ALCAR seems to exert a number of central nervous system (CNS)-related effects, even though a clear pharmacol. action that could explain clin. results in AD has not been identified yet. The aim of this study was to determine cerebrospinal fluid (CSF) and plasma biol. correlates of ALCAR effects in AD after a short-term, high-dose, i.v., open treatment. Results show that ALCAR CSF levels achieved under treatment were significantly higher than the ones at baseline, reflecting a good penetration through the blood-brain barrier and thus a direct CNS challenge. ALCAR treatment produced no apparent change on CSF classic neurotransmitters and their metabolite levels (homovanillic acid, 5-hydroxyindoleacetic acid, MHPG, dopamine, choline). Among CSF peptides, while ACTH-releasing hormone and adrenocorticotrophic hormone remained unchanged,  $\beta$ -endorphins significantly decreased after treatment; plasma cortisol levels matched this reduction. Since both CSF  $\beta$ -endorphins and plasma cortisol decreased, one possible explanation is that ALCAR reduced the AD-dependent hypothalamic-pituitary-adrenocortical (HPA) axis hyperactivity. At present, no clear explanation can be proposed for the specific mechanism of this action.  
AN 1996:163109 HCAPLUS <<LOGINID::20070716>>  
DN 124:278810  
TI Acetyl-L-carnitine in Alzheimer disease: A short-term study on CSF neurotransmitters and neuropeptides  
AU Bruno, G.; Scaccianoce, S.; Bonamini, M.; Patacchioli, F. R.; Cesarino, F.; Grassini, P.; Sorrentino, E.; Angelucci, L.; Lenzi, G. L.  
CS Dipartimento di Scienze Neurologiche, Universita di Roma "La Sapienza", Rome, Italy  
SO Alzheimer Disease and Associated Disorders (1995), 9(3), 128-31  
CODEN: ADADE2; ISSN: 0893-0341  
PB Lippincott-Raven  
DT Journal  
LA English

=> d his

(FILE 'HOME' ENTERED AT 12:16:05 ON 16 JUL 2007)

FILE 'REGISTRY' ENTERED AT 12:16:14 ON 16 JUL 2007

L1 1 S MIZOLASTINE/CN

FILE 'STNGUIDE' ENTERED AT 12:16:29 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:19:16 ON 16 JUL 2007

L2 209 S L1

L3 28832 S (SUSTAINED OR CONTROLLED OR DELAYED OR SLOW) (W) RELEASE

L4 145377 S CASTOR OR LECITHIN OR WAX OR (FATTY MATRIX)

L5 533364 S MALEC OR MALEATE OR TARTARIC OR TARTARATE OR MALIC OR MALATE

FILE 'STNGUIDE' ENTERED AT 12:19:20 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:20:23 ON 16 JUL 2007

L6 47754 S (SUSTAINED OR CONTROLLED OR DELAYED OR SLOW) (W) RELEASE

L7 8 S L2 AND L6 AND L5

L8 3 S L7 AND L4

FILE 'STNGUIDE' ENTERED AT 12:20:27 ON 16 JUL 2007

L9 FILE 'HCAPLUS' ENTERED AT 12:20:53 ON 16 JUL 2007  
 1 S L7 AND (PY<1999 OR AY<1999 OR PRY<1999)  
 FILE 'STNGUIDE' ENTERED AT 12:20:56 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:21:03 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:21:04 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:21:32 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:21:32 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:22:06 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:22:06 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:23:23 ON 16 JUL 2007  
 L10 400 S L6 AND L4 AND L5  
 L11 144 S L10 AND (PY<1999 OR AY<1999 OR PRY<1999)  
 FILE 'STNGUIDE' ENTERED AT 12:23:27 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:23:46 ON 16 JUL 2007  
 L12 7229 S ANTIHISTAMINE  
 L13 0 S L11 AND L12  
 FILE 'STNGUIDE' ENTERED AT 12:23:49 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:24:14 ON 16 JUL 2007  
 L14 49959 S TABLET  
 L15 47 S L11 AND L14  
 FILE 'STNGUIDE' ENTERED AT 12:24:17 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:24:41 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:24:42 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:24:53 ON 16 JUL 2007  
 L16 34 S L15 AND (PY<1997 OR PRY<1997 OR AY<1997)  
 FILE 'STNGUIDE' ENTERED AT 12:24:57 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:25:06 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:25:07 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:27:23 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:27:24 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:33:34 ON 16 JUL 2007  
 L17 4 S L2 AND L5 AND L14  
 L18 2713 S (PHARMACEUTICALLY ACCEPTABLE) (W) (EXCIPIENT OR DILUENT OR CARR  
 FILE 'STNGUIDE' ENTERED AT 12:33:37 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:34:15 ON 16 JUL 2007  
 L19 255 S L18 AND L5  
 FILE 'STNGUIDE' ENTERED AT 12:34:18 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:35:00 ON 16 JUL 2007



L20            53 S L19 AND (PY<1996 OR AY<1996 OR PRY<1996)

FILE 'STNGUIDE' ENTERED AT 12:35:04 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:35:19 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:35:20 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:37:09 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:37:10 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:38:06 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:38:07 ON 16 JUL 2007

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:54:33 ON 16 JUL 2007

SEA MIZOLASTINE(W) (MALEATE OR CITRATE OR TARTRATE OR MALATE OR

L21            -----  
               QUE MIZOLASTINE(W) (MALEATE OR CITRATE OR TARTRATE OR MALATE OR  
               -----  
               SEA MIZOLASTINE(W)?ATE  
               -----  
               0\* FILE ADISCTI  
               SEA L5(5A)L18  
               -----

FILE 'HCAPLUS' ENTERED AT 13:17:19 ON 16 JUL 2007

L22            9 S L5(5A)L18

FILE 'STNGUIDE' ENTERED AT 13:17:21 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:17:58 ON 16 JUL 2007

L23            1 S L22 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:18:02 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:18:11 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 13:18:11 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:20:50 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 13:20:52 ON 16 JUL 2007

L24            0 S L5 AND ((ALLREGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT

L25            0 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:08 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:21:20 ON 16 JUL 2007

L26            939 S L5 AND ((ALLREGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT

L27            695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:25 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:21:38 ON 16 JUL 2007

L28            1081 S L5 AND ((ALLERGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT

L29            695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:42 ON 16 JUL 2007

L30 FILE 'HCAPLUS' ENTERED AT 13:22:12 ON 16 JUL 2007  
L31 163 S L5 (6A) ((ALLERGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANTI  
695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:22:17 ON 16 JUL 2007

L32 FILE 'HCAPLUS' ENTERED AT 13:22:37 ON 16 JUL 2007  
103 S L30 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:22:41 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:22:54 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 13:22:54 ON 16 JUL 2007

L33 FILE 'REGISTRY' ENTERED AT 14:08:07 ON 16 JUL 2007  
EXP L-ARGININE-2-PYRROLIDONE-5-CARBOXYLATE/CN  
L34 1 S MALTODEXTRIN/CN  
2 S LYSINE/CN

FILE 'STNGUIDE' ENTERED AT 14:09:27 ON 16 JUL 2007

L35 FILE 'REGISTRY' ENTERED AT 14:13:35 ON 16 JUL 2007  
EXP ACETYL-L-CARNITINE/CN  
1 S E3

FILE 'STNGUIDE' ENTERED AT 14:14:01 ON 16 JUL 2007

L36 FILE 'HCAPLUS' ENTERED AT 14:15:48 ON 16 JUL 2007  
L37 2 S L-ARGININE-2-PYRROLIDONE-5-CARBOXYLATE  
L38 1041 S L35  
L39 55755 S L33 OR L34  
L40 1 S L36 AND L37 AND L38  
94029 S CORTISOL OR (HUMAN GROWTH HORMONE) OR EXERCISE OR BODYBUILDIN

FILE 'STNGUIDE' ENTERED AT 14:15:54 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:16:06 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:16:07 ON 16 JUL 2007

L41 FILE 'HCAPLUS' ENTERED AT 14:17:07 ON 16 JUL 2007  
L42 1 S L36 AND L37  
75 S L37 AND L40

FILE 'STNGUIDE' ENTERED AT 14:17:10 ON 16 JUL 2007

L43 FILE 'HCAPLUS' ENTERED AT 14:17:36 ON 16 JUL 2007  
54 S L42 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 14:17:39 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:17:52 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:17:53 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:22:05 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:22:06 ON 16 JUL 2007

=> log hold		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	321.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-39.78

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 14:22:18 ON 16 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXQ1623

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'STNGUIDE' AT 14:44:14 ON 16 JUL 2007  
FILE 'STNGUIDE' ENTERED AT 14:44:14 ON 16 JUL 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)d

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	321.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-39.78

=> d l36 1-2 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L36 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Nutritional supplement for enhancing the production and effect of natural human growth hormone

L36 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI A study of growth hormone release in man after oral administration of amino acids

=> log hold

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	324.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-39.78

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 14:44:24 ON 16 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'STNGUIDE' AT 15:11:30 ON 16 JUL 2007  
FILE 'STNGUIDE' ENTERED AT 15:11:30 ON 16 JUL 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	324.58
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-39.78

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.18	324.70
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-39.78

FILE 'HCAPLUS' ENTERED AT 15:13:35 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4  
FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s bee(w)pollen

7192 BEE  
19767 POLLEN  
L44 268 BEE(W) POLLEN

=> s colustrum

L45 15 COLUSTRUM

=> s lycopene

L46 5582 LYCOPENE

=> s macuna pruriens

6 MACUNA  
253 PRURIENS  
L47 1 MACUNA PRURIENS  
(MACUNA (W) PRURIENS)

=> s glycerylphosphorylcholine

L48 433 GLYCERYLPHOSPHORYLCHOLINE

=> s (growth hormone) or anabolic or bodybuilding

1359998 GROWTH  
293189 HORMONE  
47186 GROWTH HORMONE  
(GROWTH (W) HORMONE)  
11440 ANABOLIC  
44 BODYBUILDING  
L49 57749 (GROWTH HORMONE) OR ANABOLIC OR BODYBUILDING

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.60	327.30
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-39.78

FILE 'STNGUIDE' ENTERED AT 15:13:41 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.12	327.42
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-39.78

FILE 'HCAPLUS' ENTERED AT 15:14:35 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4  
FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l44 and l49

L50 3 L44 AND L49

=> s l45 and l49

L51 0 L45 AND L49

=> s l46 and l49

L52 14 L46 AND L49

=> s l48 and l49

L53 5 L48 AND L49

=> d l47 ti abs bib

L47 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Studies on leguminous seeds. III

AB The seeds of 20 plant species belonging to Papillonaceae were studied for their fatty acid and mineral compns. The fat and protein contents were 2-30% and 21-45% resp. The seed oils were rich in C-18 unsatd. acid (40.5-77.2%).

AN 1986:405369 HCAPLUS <<LOGINID::20070716>>

DN 105:5369

TI Studies on leguminous seeds. III

AU Chowdhury, A. R.; Banerji, R.; Tiwari, S. R.; Misra, G.; Nigam, S. K.

CS Lipid Pestic. Div., Natl. Bot. Res. Inst., Lucknow, 226001, India

SO Fette, Seifen, Anstrichmittel (1986), 88(4), 144-6

CODEN: FSASAX; ISSN: 0015-038X

DT Journal

LA English

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.43	332.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.78	-40.56

FILE 'STNGUIDE' ENTERED AT 15:14:40 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> d l50 1-3 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L50 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Regulatory mechanism of food factors in bone metabolism and prevention of osteoporosis

AB A review. Aging induces a decrease in bone mass, and osteoporosis with its accompanying decrease in bone mass is widely recognized as a major public health problem. Bone loss with increasing age may be due to decreased bone formation and increased bone resorption. Pharmacol. and nutritional factors may prevent bone loss with aging, although chemical compds. in food and plants which act on bone metabolism are poorly understood. We have found that isoflavones (including genistein and daidzein), which are contained in soybeans, have a stimulatory effect on osteoblastic bone formation and an inhibitory effect on osteoclastic bone resorption, thereby increasing bone mass. Menaquinone-7, an analog of vitamin K2 which is abundant in fermented soybeans, has been demonstrated to stimulate osteoblastic bone formation and to inhibit osteoclastic bone resorption. Of various carotenoids,  $\beta$ -cryptoxanthin, which is abundant in Satsuma mandarin (*Citrus unchiu* MARC), has a stimulatory effect on osteoblastic bone formation and an inhibitory effect on osteoclastic bone resorption. The supplementation of these factors has a preventive effect on bone loss induced by ovariectomy in rats, which are an animal model of osteoporosis, and their intake has been shown to have a stimulatory effect on bone mass in humans. Factors with an anabolic effect on bone metabolism were found in exts. obtained from wasabi leafstalk (*Wasabi japonica* MATSUM), the marine alga *Sargassum horneri*, and bee pollen *Cistus ladaniferus*. Phytocomponent p-hydroxycinnamic acid was also found to have an anabolic effect on bone metabolism. Food chemical factors thus play a role in bone health and may be important in the prevention of bone loss with increasing age.

AN 2007:22523 HCAPLUS <<LOGINID::20070716>>

DN 146:80970

TI Regulatory mechanism of food factors in bone metabolism and prevention of osteoporosis

AU Yamaguchi, Masayoshi

CS Laboratory of Endocrinology and Molecular Metabolism, Graduate School of Nutritional Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka City, 422-8526, Japan

SO Yakugaku Zasshi (2006), 126(11), 1117-1137

CODEN: YKKZAJ; ISSN: 0031-6903

PB Pharmaceutical Society of Japan

DT Journal; General Review

LA English

RE.CNT 124 THERE ARE 124 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L50 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Characterization of the active component in bee pollen  
*Cistus ladaniferus* extract in stimulating bone calcification and in inhibiting bone resorption in vitro

AB The bee pollen *Cistus ladaniferus* (*C. ladaniferus*) extract has an anabolic effect on bone metabolism. The effects of the fractionated exts. obtained from bee pollen on bone calcium content and osteoclast-like cell formation in vitro were investigated. Rat femoral-diaphyseal and -metaphyseal tissues were cultured for 48 h in a medium containing either vehicle or a water-solubilized extract with the membrane fractions obtained from bee pollen. The active component of bee pollen in increasing calcium content in diaphyseal tissues was seen in the fraction of mol. weight (MW) of less than 1000, and it was not observed in fractions of greater than MW 1000. Culture with the fractionated bee pollen extract (25 or 50  $\mu$ g/mL of medium) of less than MW 1000 caused a significant increase in calcium content in the diaphyseal or metaphyseal tissues. The parathyroid hormone (PTH;  $10^{-6}$  M)-induced decrease in diaphyseal calcium content was significantly prevented in the

presence of the fractionated bee pollen exts. (10 µg/mL) of less than MW 1000 or greater than MW 1000. Mouse marrow cells were cultured for 7 days in a medium containing PTH (10<sup>-6</sup> M) in the presence or absence of the fractionated bee pollen extract (10 or 50 µg/mL). The PTH-induced increase in osteoclast-like cell formation was markedly suppressed in the presence of exts. of less than MW 1000 as compared with that in the presence of fractions of greater than MW 1000. The effects of the fractionated bee pollen exts. of less than MW 1000 in increasing diaphyseal calcium content and in inhibiting PTH-induced osteoclastic cell formation were significantly decreased upon heat treatment for 20 and 60 min at 80°C. This study demonstrates that the active component of bee pollen *C. ladaniferus* extract, which stimulates bone formation and inhibits osteoclastic bone resorption, is the fraction with MW less than 1000.

AN 2006:1166687 HCAPLUS <<LOGINID::20070716>>

DN 145:488484

TI Characterization of the active component in bee pollen

*Cistus ladaniferus* extract in stimulating bone calcification and in inhibiting bone resorption in vitro

AU Hamamoto, Reiko; Ishiyama, Kaori; Hashimoto, Ken; Yamaguchi, Masayoshi

CS Lab. Endocrinol. Mol. Metab., Grad. Sch. Nutr. Sci., University of Shizuoka, Shizuoka, 422-8526, Japan

SO Journal of Health Science (2006), 52(5), 607-612

CODEN: JHSCFD; ISSN: 1344-9702

PB Pharmaceutical Society of Japan

DT Journal

LA English

L50 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Anabolic effects of bee pollen *Cistus*

*ladaniferus* extract on bone components in the femoral-diaphyseal and -metaphyseal tissues of rats in vitro and in vivo

AB The effects of bee pollen extract on bone components in

the femoral-diaphyseal (cortical bone) and -metaphyseal (trabecular bone)

tissues of rats in vitro and in vivo were investigated. Bone tissues were cultured for 48 h in serum-free Dulbecco's modified Eagle's medium containing either vehicle or water- or ethanol-solubilized exts. (10, 100, or 1000 µg/mL of medium) obtained from the bee pollen of

*Cistus ladaniferus*. Calcium content in the femoral-diaphyseal or -metaphyseal tissues was significantly increased in the presence of water-solubilized extract (100 or 1000 µg/mL) and ethanol-solubilized extract (1000 µg/mL). An increase was also observed in the presence of

water-solubilized extract (100 µg/mL) obtained from *Fagopyrum esculentum*, *Camellia sinensis*, or *Brassica napus* L. Alkaline phosphatase activity and DNA

content in the femoral-diaphyseal or -metaphyseal tissues in vitro were significantly increased in the presence of water-solubilized extract (100 or 1000 µg/mL) obtained from the bee pollen. The

effects of the bee pollen extract (100 µg/mL) in increasing bone components were completely inhibited in the presence of cycloheximide (10<sup>-6</sup> M), an inhibitor of protein synthesis, in vitro.

Moreover, the calcium content and alkaline phosphatase activity in the femoral-diaphyseal or -metaphyseal tissues were significantly increased by the oral administration of water-solubilized exts. (5 or 10 mg/100 g body weight) obtained from the bee pollen of *Cistus*

*ladaniferus* once daily for 7 days. The DNA content in the diaphyseal or metaphyseal tissues was significantly increased by the oral administration of water-solubilized extract (10 mg/100 g) of bee pollen

*cistus*. The dose of 1.0 mg/100 g caused a significant increase in the diaphyseal and metaphyseal alkaline phosphatase activity or the metaphyseal DNA content in vivo. This study demonstrates that the extract of bee pollen has an anabolic effect on bone components in rats in vitro and in vivo.

AN 2006:206622 HCAPLUS <<LOGINID::20070716>>



DN 144:324694  
 TI Anabolic effects of bee pollen Cistus  
 ladaniferus extract on bone components in the femoral-diaphyseal and  
 -metaphyseal tissues of rats in vitro and in vivo  
 AU Yamaguchi, Masayoshi; Hamamoto, Reiko; Uchiyama, Satoshi; Ishiyama, Kaori;  
 Hashimoto, Ken  
 CS Lab. Endocrinol. Mol. Metab., Grad. Sch. Nutr. Sci., University of  
 Shizuoka, Shizuoka, 422-8526, Japan  
 SO Journal of Health Science (2006), 52(1), 43-49  
 CODEN: JHSCFD; ISSN: 1344-9702  
 PB Pharmaceutical Society of Japan  
 DT Journal  
 LA English

=> d 153 1-5 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L53 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Dietary supplement for promoting healthy hormonal balance

L53 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI GH responses to GH-RH in old subjects and in patients with senile dementia  
 of the Alzheimer's type: The effects of an acetylcholine precursor

L53 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Alpha-glycerylphosphorylcholine administration increases the GH  
 responses to GH-RH of young and elderly subjects

L53 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effects of a metabolic endurance test of seminal and endocrine parameters  
 in young bulls

L53 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Choline, nutrient and metabolite of Hansenula anomala

=> d 153 2 3 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L53 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI GH responses to GH-RH in old subjects and in patients with senile dementia  
 of the Alzheimer's type: The effects of an acetylcholine precursor

AB The results document that the pituitary responsiveness to GHRH in patients  
 with senile dementia of Alzheimer type (SDAT) is similar to that of normal  
 subjects, confirming previously reported data on this topic. The  
 increased cholinergic transmission induced by alpha-  
 glycerylphosphorylcholine (alpha-GFC) administration was followed  
 by an enhancement of GH responses to GHRH (a four-fold increase) of the  
 same entity in normal elderly subjects and in SDAT patients. These  
 results extend previous observations on the GH release potentiating effect  
 of alpha-GFC which were documented in normal young and old subjects with  
 an alpha-GFC dose of 1 g. The mechanism by which alpha-GFC increases  
 GHRH-stimulated secretion is probably due to an inhibition of somatostatin  
 (SRIF) release caused by an increased hypothalamic cholinergic tone.  
 Furthermore the lack of difference between normal old subjects and  
 patients with SDAT both in the GH responses to GHRH and in the  
 potentiating effect of GH release by a cholinergic precursor, like  
 alpha-GFC, suggest that the neurochem. abnormalities of AD (the decrease  
 in SRIF concentration and CAT activity documented in several brain areas) are

not

associated with major modifications of pituitary sensitivity to GHRH.  
AN 1993:623310 HCAPLUS <<LOGINID::20070716>>  
DN 119:223310  
TI GH responses to GH-RH in old subjects and in patients with senile dementia  
of the Alzheimer's type: The effects of an acetylcholine precursor  
AU Ceda, G. P.; Marzani, G. P.; Piovani, E.; Bianchini, A.; Tontodonati, V.;  
Valenti, G.  
CS Univ. Parma, Parma, 43100, Italy  
SO Advances in the Biosciences (Oxford) (1993), 87(Alzheimer's Disease and  
Related Disorders), 425-8  
CODEN: AVBIB9; ISSN: 0065-3446  
DT Journal  
LA English

L53 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Alpha-glycerylphosphorylcholine administration increases the GH  
responses to GH-RH of young and elderly subjects  
AB GH secretion is decreased during aging in humans and in rodents. This  
decrease may be due to increased hypothalamic somatostatin release, which  
is inhibited by cholinergic agonists, or to decreased secretion of GHRH.  
 $\alpha$ - Glycerylphosphorylcholine ( $\alpha$ -GPC) is a putative  
acetylcholine precursor used in the treatment of cognitive disorders in  
the elderly. In order to learn what effect  $\alpha$ -GPC had on GH  
secretion, GHRH was given to young and old human volunteers, with or  
without the addition of  $\alpha$ -GPC. GH secretion was greater in the younger  
subjects than in the old individuals, and both groups had a greater GH  
response to the GHRH +  $\alpha$ -GPC than to GHRH alone. The potentiating  
effect of  $\alpha$ -GPC on GH secretion was more pronounced in the elderly  
subjects. These findings confirm the observation that aged individuals  
respond less well to GHRH than younger subjects, and provides further  
evidence that increased cholinergic tone enhances GH release.

AN 1992:248952 HCAPLUS <<LOGINID::20070716>>  
DN 116:248952  
TI Alpha-glycerylphosphorylcholine administration increases the GH  
responses to GH-RH of young and elderly subjects  
AU Ceda, G. P.; Ceresini, G.; Denti, L.; Marzani, G.; Piovani, E.; Banchini,  
A.; Tarditi, E.; Valenti, G.  
CS Univ. Parma, Parma, Italy  
SO Hormone and Metabolic Research (1992), 24(3), 119-21  
CODEN: HMMRA2; ISSN: 0018-5043  
DT Journal  
LA English

=> d l52 1-14 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L52 ANSWER 1 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Topical formulation for integument cell regeneration comprising stem cell  
or growth factors and/or antioxidants

L52 ANSWER 2 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Effect of postharvest ethylene treatment on carotenoid accumulation and  
the expression of carotenoid biosynthetic genes in the flavedo of orange  
(Citrus sinensis L. Osbeck) fruit

L52 ANSWER 3 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Osteoporosis prevention by beta-cryptoxanthin

L52 ANSWER 4 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Topical delivery system comprising esters of hydroxy acids for cosmetic  
and pharmaceutical agents

L52 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Galactomannans and/or glucomannans for increasing the bioavailability of active substances

L52 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Nutritional supplement for enhancing the production and effect of natural human growth hormone

L52 ANSWER 7 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Investigation of factors influencing production of the monocyclic carotenoid torulene in metabolically engineered Escherichia coli

L52 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Nutraceutical compositions and food supplements containing NADH, ATP, antioxidants and optionally zinc

L52 ANSWER 9 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effect of carotenoid on calcium content and alkaline phosphatase activity in rat femoral tissues in vitro: The unique anabolic effect of  $\beta$ -cryptoxanthin

L52 ANSWER 10 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Engineering fruit quality via novel genetic intervention

L52 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Determining the effect of compounds on the ability of a subject to control their weight and compositions to reduce the effect of such compounds

L52 ANSWER 12 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Constructing novel combinations of genes for metabolic enzymes in the development of novel anabolic and catabolic pathways and metabolic products

L52 ANSWER 13 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Oil-in-water emulsion compositions for polyfunctional active ingredients

L52 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Method of metabolic adjuvation and cellular repair comprising vitamins, minerals, and plant extracts

=> d 152 5 6 8 11 14 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L52 ANSWER 5 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Galactomannans and/or glucomannans for increasing the bioavailability of active substances

AB The invention relates to a method for increasing the bioavailability of nutrients by using polysaccharides such as galactomannans and similar for introducing active substances, e.g. the human growth hormone HGH and others, into the human or animal metabolism. The aim of the invention is to further develop the production of polysaccharides such as galactomannans and glucomannans in such a way that the same are also suitable for introducing active substances such as the human growth hormone into the human or animal metabolism. Thus granules containing active substance coenzyme Q10 were prepared by mixing 62 kg of guar flour and a solution of 18 kg of coenzyme Q10 and 18 kg of DL- $\alpha$ -tocopherol acetate (antioxidant) in 15 kg of iso-Pr alc., and adding water until the product reached the maximum moisture content, resulting in swelling of the polysaccharide matrix and immobilization of the coenzyme Q10 by penetrating the polysaccharide chains. By subsequent

drying under vacuum conditions, the moisture was removed from the product at room temperature to a residual moisture content of 5 to 7%, and the product was thus stabilized. The cake formed on drying was crushed and brought to the desired particle size of 0.2 to 2 mm by sieving.

AN 2005:962090 HCAPLUS <<LOGINID::20070716>>  
DN 143:235537  
TI Galactomannans and/or glucomannans for increasing the bioavailability of active substances  
IN Hefel, Andreas  
PA Wheli Inter A.-G., Switz.  
SO PCT Int. Appl., 27 pp.  
CODEN: PIXXD2  
DT Patent  
LA German  
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005079857	A1	20050901	WO 2005-EP1546	20050216
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005181058	A1	20050818	US 2004-780152	20040217
	DE 102004008017	A1	20051103	DE 2004-102004008017	20040317
	CN 1842348	A	20061004	CN 2005-80000949	20050216
	EP 1720579	A1	20061115	EP 2005-715350	20050216
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRAI	US 2004-780152	A	20040217		
	DE 2004-102004008017	A	20040317		
	WO 2005-EP1546	W	20050216		

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L52 ANSWER 6 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Nutritional supplement for enhancing the production and effect of natural human growth hormone  
AB A nutritional supplement for enhancing the production and effect of natural human growth hormone includes: L-arginine-2-pyrrolidone-5-carboxylate in an amount of about 500 mg to about 10 g; L-lysine-HCl in an amount of about 500 mg to about 10 g; and a cortisol suppressant including at least one of acetyl-L-carnitine in an amount of about 1 g to about 10 g and maltodextrin in an amount of about 1 g to about 10 g.

AN 2005:570531 HCAPLUS <<LOGINID::20070716>>  
DN 143:83512  
TI Nutritional supplement for enhancing the production and effect of natural human growth hormone  
IN Nerenberg, Arnold P.  
PA USA  
SO U.S. Pat. Appl. Publ., 7 pp.  
CODEN: USXXCO  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

PI US 2005143343 A1 20050630 US 2003-748615 20031230  
 PRAI US 2003-748615 20031230

L52 ANSWER 8 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Nutraceutical compositions and food supplements containing NADH, ATP, antioxidants and optionally zinc

AB The present invention refers to nutraceutical compns. and food supplements comprising NADH, ATP and antioxidants, in particular resveratrol and lycopene, and optionally zinc. The compns. according to the invention are capable of stimulating the physiol. production of energy (pro-energetic and antiasthenic activity).

AN 2004:2609 HCAPLUS <<LOGINID::20070716>>

DN 140:41172

TI Nutraceutical compositions and food supplements containing NADH, ATP, antioxidants and optionally zinc

IN Perani, Aldo

PA Dietetic S.P.A., Italy

SO PCT Int. Appl., 8 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004000043	A2	20031231	WO 2003-EP6256	20030613
	WO 2004000043	A3	20040304		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	IT 2002MI1366	A1	20031222	IT 2002-MI1366	20020621
	AU 2003246430	A1	20040106	AU 2003-246430	20030613
	EP 1531690	A2	20050525	EP 2003-760616	20030613
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
PRAI	IT 2002-MI1366	A	20020621		
	WO 2003-EP6256	W	20030613		

L52 ANSWER 11 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Determining the effect of compounds on the ability of a subject to control their weight and compositions to reduce the effect of such compounds

AB A method of determining the extent of the effect of a target compound on the ability of a test subject to control their weight. The method comprises the steps of determining the degree or severity by which the compound affects each of a plurality of weight controlling systems present in the subject, determining the persistence of the compound in the subject and calculating the effect as a function of these values. The effect of target compds. including pesticides, environmental pollutants, organic solvents and heavy metals may be determined. Weight controlling systems that may be considered include the hormonal system, metabolism and muscular activity. A method of determining the effect of an item on the ability of a subject to control their weight comprises determining the amount in the item of a plurality of target compds. which effect the ability of the subject to control their weight. A method of determining the extent to which a subject has had their ability to control their weight inhibited comprises determining the amount in the subject of a plurality of

comps. which have an effect on the ability of the subject to control their weight Compns. to reduce the effect of one or more target comps. present in a subject which effect the ability of the subject to control their weight comprise one or more micronutrients or target compound absorbants which reduce the level of and/or counteract the effect of the target comps. The comps. may be used in the treatment of obesity.

AN 2002:922003 HCAPLUS <<LOGINID::20070716>>

DN 137:363100

TI Determining the effect of compounds on the ability of a subject to control their weight and compositions to reduce the effect of such compounds

IN Buchanan-Baillie-Hamilton, Paula Frances; Peck, Julian Claude

PA UK

SO Brit. UK Pat. Appl., 89 pp.

CODEN: BAXXDU

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2370504	A	20020703	GB 2001-17052	20010712
	WO 2002012882	A3	20020425	WO 2001-GB3554	20010807
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	GB 2000-19327	A	20000808		
	GB 2001-17052	A	20010712		

L52 ANSWER 14 OF 14 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Method of metabolic adjuvation and cellular repair comprising vitamins, minerals, and plant extracts

AB A multi-agent tri-daily comestible of vitamins, minerals, plant exts., amino acids, neurochem. precursors, enzymes, and pH-regulating agents which supply key elements necessary for proper metabolism and function of the human body delivered at specific times of the daily biocycle when the need for such specific agents exists in order to maximize the body's extra- and intra-cellular matrix to cellular and biochem. protective and repair mechanisms utilized to deter the effects of otherwise normal aging. Formulation of the nutritional supplement of the invention is disclosed.

AN 1999:273547 HCAPLUS <<LOGINID::20070716>>

DN 130:301715

TI Method of metabolic adjuvation and cellular repair comprising vitamins, minerals, and plant extracts

IN Giampapa, Vincent C.

PA Longevity Institute International, USA

SO U.S., 9 pp., Cont.-in-part of U.S. Ser. No. 688,267, abandoned.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5895652	A	19990420	US 1997-898090	19970723
PRAI	US 1996-688267	B2	19960729		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST	0.12	381.09
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-48.36

FILE 'HCAPLUS' ENTERED AT 15:18:13 ON 16 JUL 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4  
 FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s maltodextrin

L54 4612 MALTODEXTRIN

=> s l53 and l49

L55 5 L53 AND L49

=> file stngiude

'STNGIUDE' IS NOT A VALID FILE NAME  
 SESSION CONTINUES IN FILE 'HCAPLUS'  
 Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> d l55 1-5 ti

L55 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Dietary supplement for promoting healthy hormonal balance

L55 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI GH responses to GH-RH in old subjects and in patients with senile dementia of the Alzheimer's type: The effects of an acetylcholine precursor

L55 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Alpha-glycerylphosphorylcholine administration increases the GH responses to GH-RH of young and elderly subjects

L55 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effects of a metabolic endurance test of seminal and endocrine parameters in young bulls

L55 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Choline, nutrient and metabolite of Hansenula anomala

=> y

Y IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	4.30	385.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-48.36

FILE 'STNGUIDE' ENTERED AT 15:18:32 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	385.45
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-48.36

FILE 'HCAPLUS' ENTERED AT 15:19:12 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4  
FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l54 and l49

L56 15 L54 AND L49

=> file stnguide



COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	2.60	388.05
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-48.36

FILE 'STNGUIDE' ENTERED AT 15:19:14 ON 16 JUL 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
 LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	0.06	388.11
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-48.36

FILE 'HCAPLUS' ENTERED AT 15:19:31 ON 16 JUL 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4  
 FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l56 and (PY<2003 or AY<2003 or PRY<2003)

22885849 PY<2003  
 4448261 AY<2003  
 3926713 PRY<2003

L57 9 L56 AND (PY<2003 OR AY<2003 OR PRY<2003)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	2.60	390.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00 -48.36

FILE 'STNGUIDE' ENTERED AT 15:19:35 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> d 157 1-9 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L57 ANSWER 1 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Sustained-release microencapsulated delivery systems containing naturally derived oils

L57 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Agglomerated granular protein-rich nutritional supplement

L57 ANSWER 3 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Compositions and methods for the pulmonary delivery of aerosolized medicaments

L57 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Dietary supplement for promoting healthy hormonal balance

L57 ANSWER 5 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Sustained-release microencapsulated delivery system

L57 ANSWER 6 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Oral transmucosal drug dosage using solid solution

L57 ANSWER 7 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Formulation and use of transforming growth factor  $\beta$  and anabolic growth factors in the treatment and prevention of diseases of the intestinal mucosa

L57 ANSWER 8 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Short-term creatine supplementation does not alter the hormonal response to resistance training

L57 ANSWER 9 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Compositions of oral dissolvable medicaments

=> d 157 2 4 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L57 ANSWER 2 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Agglomerated granular protein-rich nutritional supplement

AB An agglomerated granular protein-rich nutritional supplement comprises a mixture of: 13-100 percent by weight edible food proteins; 0-57 percent by weight

edible carbohydrates; 0-10 percent by weight edible fats; 0-15 percent by weight

edible dietary vitamins and minerals; 0-78 percent by weight edible amino acids; 0-10 percent by weight edible plant exts., and up to 4 percent by weight chondroitin sulfate, where the nutritional supplement is agglomerated and granulated in an oral unit dosage form that is directly absorbable onto the tongue or rapidly dissolvable in an aqueous liquid Specific formulations

of

the supplement are disclosed, for use by specific groups of individuals. A method of supplementing the nutritional intake of individuals engaged in bodybuilding and protein supplementation, meal replacement, exercise recovery or mass gaining, comprising orally administering a formulation of the protein-rich nutritional supplement. A method of augmenting the mental acuity and energy of humans, comprising orally administering another formulation of the protein-rich nutritional supplement. Methods also are disclosed for supplementing the nutritional intake of women, male bodybuilders, children and adolescents, and older adults. In all methods, the nutritional supplement is in an oral unit dosage form of either agglomerated granules or a rapidly dissolvable wafer and also includes a flavoring compound and an effervescent compound

AN 2004:310653 HCAPLUS <<LOGINID::20070716>>

DN 140:320327

TI Agglomerated granular protein-rich nutritional supplement

IN Lockwood, Christopher

PA USA

SO U.S. Pat. Appl. Publ., 16 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004071825	A1	20040415	US 2002-271239	20021015 <--
	WO 2004034986	A2	20040429	WO 2003-US32646	20031015 <--
	WO 2004034986	A3	20050120		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2003287150	A1	20040504	AU 2003-287150	20031015 <--
PRAI	US 2002-271239	A	20021015	<--	
	WO 2003-US32646	W	20031015		

L57 ANSWER 4 OF 9 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Dietary supplement for promoting healthy hormonal balance

AB A dietary supplement for promoting healthy hormonal balance in adult human subjects, and especially in elderly subjects, comprises a secretagogue for stimulating the release of human growth hormone (hGH)

by the pituitary, and the conversion by hGH to insulin-like growth factor 1 (IGF-1), in combination with 7-keto-dehydroepiandrosterone (7-keto DHEA). The dietary supplement also includes other interacting ingredients for delivering antioxidants for retarding damage at the cellular level caused by the presence of free radicals, and natural herbs for promoting physiol. health. For example, an essentially dry powder constituting a dietary supplement of this invention, to be dissolved in water to provide a daily serving, contained 7-keto-DHEA 25 mg, Symbiotropin 1000 mg, lecithin 200 mg, maltodextrin 7.227 mg, citric acid 640 mg, dipotassium phosphate 25 mg, potassium citrate 25 mg, probiotic blend 100 mg, fruco-oligosaccharides 400 mg, S-adenosyl-L-methionine 5 mg, acetyl-L-carnitine 100 mg, omega-3 fatty acids (Dry n-3) 125 mg, trimethylglycine 100 mg, coenzyme Q10 7.5 mg, resveratrol (Protokin) 10 mg,  $\alpha$ -lipoic acid 50 mg, L-glutathione 30 mg, N-acetylcysteine 200 mg, and flavoring agents 300 mg.

AN 2002:271056 HCAPLUS <<LOGINID::20070716>>

DN 136:299719

TI Dietary supplement for promoting healthy hormonal balance

IN Hastings, Carl W.; Barnes, David J.; Daley, Christine A.  
PA Reliv' International, Inc., USA  
SO U.S., 5 pp.  
CODEN: USXXAM  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6368617	B1	20020409	US 2001-858047	20010515 <--
PRAI	US 2001-858047		20010515	<--	
RE.CNT	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

=> d his

(FILE 'HOME' ENTERED AT 12:16:05 ON 16 JUL 2007)

L1 FILE 'REGISTRY' ENTERED AT 12:16:14 ON 16 JUL 2007  
1 S MIZOLASTINE/CN

FILE 'STNGUIDE' ENTERED AT 12:16:29 ON 16 JUL 2007

L2 FILE 'HCAPLUS' ENTERED AT 12:19:16 ON 16 JUL 2007  
209 S L1  
L3 28832 S (SUSTAINED OR CONRTOLLED OR DELAYED OR SLOW) (W) RELEASE  
L4 145377 S CASTOR OR LECITHIN OR WAX OR (FATTY MATRIX)  
L5 533364 S MALEC OR MALEATE OR TARTARIC OR TARTARATE OR MALIC OR MALATE

FILE 'STNGUIDE' ENTERED AT 12:19:20 ON 16 JUL 2007

L6 FILE 'HCAPLUS' ENTERED AT 12:20:23 ON 16 JUL 2007  
47754 S (SUSTAINED OR CONTROLLED OR DELAYED OR SLOW) (W) RELEASE  
L7 8 S L2 AND L6 AND L5  
L8 3 S L7 AND L4

FILE 'STNGUIDE' ENTERED AT 12:20:27 ON 16 JUL 2007

L9 FILE 'HCAPLUS' ENTERED AT 12:20:53 ON 16 JUL 2007  
1 S L7 AND (PY<1999 OR AY<1999 OR PRY<1999)

FILE 'STNGUIDE' ENTERED AT 12:20:56 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:21:03 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:21:04 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:21:32 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:21:32 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:22:06 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:22:06 ON 16 JUL 2007

L10 FILE 'HCAPLUS' ENTERED AT 12:23:23 ON 16 JUL 2007  
400 S L6 AND L4 AND L5  
L11 144 S L10 AND (PY<1999 OR AY<1999 OR PRY<1999)

FILE 'STNGUIDE' ENTERED AT 12:23:27 ON 16 JUL 2007

L12 FILE 'HCAPLUS' ENTERED AT 12:23:46 ON 16 JUL 2007  
7229 S ANTIHISTAMINE

L13                    0 S L11 AND L12

FILE 'STNGUIDE' ENTERED AT 12:23:49 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:24:14 ON 16 JUL 2007

L14                    49959 S TABLET

L15                    47 S L11 AND L14

FILE 'STNGUIDE' ENTERED AT 12:24:17 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:24:41 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:24:42 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:24:53 ON 16 JUL 2007

L16                    34 S L15 AND (PY<1997 OR PRY<1997 OR AY<1997)

FILE 'STNGUIDE' ENTERED AT 12:24:57 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:25:06 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:25:07 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:27:23 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:27:24 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:33:34 ON 16 JUL 2007

L17                    4 S L2 AND L5 AND L14

L18                    2713 S (PHARMACEUTICALLY ACCEPTABLE) (W) (EXCIPIENT OR DILUENT OR CARR

FILE 'STNGUIDE' ENTERED AT 12:33:37 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:34:15 ON 16 JUL 2007

L19                    255 S L18 AND L5

FILE 'STNGUIDE' ENTERED AT 12:34:18 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:35:00 ON 16 JUL 2007

L20                    53 S L19 AND (PY<1996 OR AY<1996 OR PRY<1996)

FILE 'STNGUIDE' ENTERED AT 12:35:04 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:35:19 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:35:20 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:37:09 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:37:10 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:38:06 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:38:07 ON 16 JUL 2007

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:54:33 ON 16 JUL 2007

SEA MIZOLASTINE(W) (MALEATE OR CITRATE OR TARTRATE OR MALATE OR

-----

L21                    QUE MIZOLASTINE(W) (MALEATE OR CITRATE OR TARTRATE OR MALATE OR

-----

SEA MIZOLASTINE(W) ?ATE

-----  
0\* FILE ADISCTI  
SEA L5(5A)L18  
-----

L22 FILE 'HCAPLUS' ENTERED AT 13:17:19 ON 16 JUL 2007  
9 S L5(5A)L18

FILE 'STNGUIDE' ENTERED AT 13:17:21 ON 16 JUL 2007

L23 FILE 'HCAPLUS' ENTERED AT 13:17:58 ON 16 JUL 2007  
1 S L22 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:18:02 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:18:11 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 13:18:11 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:20:50 ON 16 JUL 2007

L24 FILE 'STNGUIDE' ENTERED AT 13:20:52 ON 16 JUL 2007  
0 S L5 AND ((ALLREGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT  
L25 0 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:08 ON 16 JUL 2007

L26 FILE 'HCAPLUS' ENTERED AT 13:21:20 ON 16 JUL 2007  
939 S L5 AND ((ALLREGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT  
L27 695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:25 ON 16 JUL 2007

L28 FILE 'HCAPLUS' ENTERED AT 13:21:38 ON 16 JUL 2007  
1081 S L5 AND ((ALLERGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT  
L29 695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:42 ON 16 JUL 2007

L30 FILE 'HCAPLUS' ENTERED AT 13:22:12 ON 16 JUL 2007  
163 S L5(6A) ((ALLERGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANTI  
L31 695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:22:17 ON 16 JUL 2007

L32 FILE 'HCAPLUS' ENTERED AT 13:22:37 ON 16 JUL 2007  
103 S L30 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:22:41 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:22:54 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 13:22:54 ON 16 JUL 2007

L33 FILE 'REGISTRY' ENTERED AT 14:08:07 ON 16 JUL 2007  
EXP L-ARGININE-2-PYRROLIDONE-5-CARBOXYLATE/CN  
L34 1 S MALTODEXTRIN/CN  
2 S LYSINE/CN

FILE 'STNGUIDE' ENTERED AT 14:09:27 ON 16 JUL 2007

L35 FILE 'REGISTRY' ENTERED AT 14:13:35 ON 16 JUL 2007  
EXP ACETYL-L-CARNITINE/CN  
1 S E3

FILE 'STNGUIDE' ENTERED AT 14:14:01 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:15:48 ON 16 JUL 2007

L36 2 S L-ARGININE-2-PYRROLIDONE-5-CARBOXYLATE  
L37 1041 S L35  
L38 55755 S L33 OR L34  
L39 1 S L36 AND L37 AND L38  
L40 94029 S CORTISOL OR (HUMAN GROWTH HORMONE) OR EXERCISE OR BODYBUILDIN

FILE 'STNGUIDE' ENTERED AT 14:15:54 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:16:06 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:16:07 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:17:07 ON 16 JUL 2007

L41 1 S L36 AND L37  
L42 75 S L37 AND L40

FILE 'STNGUIDE' ENTERED AT 14:17:10 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:17:36 ON 16 JUL 2007  
L43 54 S L42 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 14:17:39 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:17:52 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:17:53 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:22:05 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:22:06 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:44:20 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:44:20 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:13:35 ON 16 JUL 2007

L44 268 S BEE(W) POLLEN  
L45 15 S COLUSTRUM  
L46 5582 S LYCOPENE  
L47 1 S MACUNA PRURIENS  
L48 433 S GLYCERYLPHOSPHORYLCHOLINE  
L49 57749 S (GROWTH HORMONE) OR ANABOLIC OR BODYBUILDING

FILE 'STNGUIDE' ENTERED AT 15:13:41 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:14:35 ON 16 JUL 2007

L50 3 S L44 AND L49  
L51 0 S L45 AND L49  
L52 14 S L46 AND L49  
L53 5 S L48 AND L49

FILE 'STNGUIDE' ENTERED AT 15:14:40 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:15:00 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:15:00 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:15:24 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:15:25 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:16:00 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:16:01 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:16:12 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:16:13 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:17:17 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:17:18 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:18:13 ON 16 JUL 2007

L54 4612 S MALTODEXTRIN

L55 5 S L53 AND L49

FILE 'STNGUIDE' ENTERED AT 15:18:32 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:19:12 ON 16 JUL 2007

L56 15 S L54 AND L49

FILE 'STNGUIDE' ENTERED AT 15:19:14 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:19:31 ON 16 JUL 2007

L57 9 S L56 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 15:19:35 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:19:41 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:19:41 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:20:14 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:20:15 ON 16 JUL 2007

=> log hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.06

404.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-49.92

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 15:20:22 ON 16 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*

SESSION RESUMED IN FILE 'STNGUIDE' AT 15:48:25 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:48:25 ON 16 JUL 2007

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)s



COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	0.06	404.81
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-49.92

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	0.18	404.93
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-49.92

FILE 'HCAPLUS' ENTERED AT 15:49:59 ON 16 JUL 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4  
 FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s mucuna

L58 487 MUCUNA

=> s bovine colostrum

167499 BOVINE  
 5846 COLOSTRUM  
 L59 554 BOVINE COLOSTRUM  
 (BOVINE (W) COLOSTRUM)

=> s 58 and 49

213197 58  
 211452 49  
 L60 13977 58 AND 49

=> s 59 and 49

165949 59  
 211452 49  
 L61 12339 59 AND 49

=> s 60 and (PY<2004 or AY<2004 or PRY<2004)

1229279 60  
23933348 PY<2004  
4729314 AY<2004  
4211172 PRY<2004  
L62 1104683 60 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s 61 and (PY<2004 or AY<2004 or PRY<2004)

179354 61  
23933348 PY<2004  
4729314 AY<2004  
4211172 PRY<2004  
L63 157831 61 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.60	407.53
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-49.92

FILE 'STNGUIDE' ENTERED AT 15:50:10 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	407.59
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-49.92

FILE 'HCAPLUS' ENTERED AT 15:50:40 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4  
FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate

substance identification.

=> s 158 and 149

L64 3 L58 AND L49

=> s 159 and 149

L65 9 L59 AND L49

=> s 164 and (PY<2004 or AY<2004 or PRY<2004)

23933348 PY<2004  
4729314 AY<2004  
4211172 PRY<2004

L66 3 L64 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> s 165 and (PY<2004 or AY<2004 or PRY<2004)

23933348 PY<2004  
4729314 AY<2004  
4211172 PRY<2004

L67 7 L65 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.60	410.19
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-49.92

FILE 'STNGUIDE' ENTERED AT 15:50:49 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> d l64 1-3 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L64 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Homeopathic composition containing plant extracts for increasing levels of hormones

AB The present invention includes a pharmacol. acceptable composition for ingestion by a mammal, having a first ingredient including a hormone or a substance which stimulates production of a hormone, such as testosterone or growth hormone. The composition also may include a second ingredient which stimulates the production of cyclic GMP. The second ingredient may also be Morinda citrifolia or an extract thereof. The composition

of the present invention increases levels of a hormone with a body. A topical composition contained herbal exts. of Eurycoma longifolia jack, Tribulus terrestris, Mucuna pruriens, Epimedium sagittatum, and Cnidium monnieri.

AN 2004:1080540 HCAPLUS <<LOGINID::20070716>>

DN 142:43826

TI Homeopathic composition containing plant extracts for increasing levels of hormones

IN Mesko, Charles A.  
 PA USA  
 SO U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S. Ser. No. 374,594.  
 CODEN: USXXCO  
 DT Patent  
 LA English  
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004253326	A1	20041216	US 2004-790417	20040301
	WO 2005084681	A1	20050915	WO 2005-US6151	20050225
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	US 2003-374594	A2	20030225		
	US 2004-790417	A	20040301		

L64 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Agglomerated granular protein-rich nutritional supplement

AB An agglomerated granular protein-rich nutritional supplement comprises a mixture of: 13-100 percent by weight edible food proteins; 0-57 percent by weight edible carbohydrates; 0-10 percent by weight edible fats; 0-15 percent by weight edible dietary vitamins and minerals; 0-78 percent by weight edible amino acids; 0-10 percent by weight edible plant exts., and up to 4 percent by weight chondroitin sulfate, where the nutritional supplement is agglomerated and granulated in an oral unit dosage form that is directly absorbable onto the tongue or rapidly dissolvable in an aqueous liquid Specific formulations

of

the supplement are disclosed, for use by specific groups of individuals. A method of supplementing the nutritional intake of individuals engaged in bodybuilding and protein supplementation, meal replacement, exercise recovery or mass gaining, comprising orally administering a formulation of the protein-rich nutritional supplement. A method of augmenting the mental acuity and energy of humans, comprising orally administering another formulation of the protein-rich nutritional supplement. Methods also are disclosed for supplementing the nutritional intake of women, male bodybuilders, children and adolescents, and older adults. In all methods, the nutritional supplement is in an oral unit dosage form of either agglomerated granules or a rapidly dissolvable wafer and also includes a flavoring compound and an effervescing compound

AN 2004:310653 HCAPLUS <<LOGINID::20070716>>

DN 140:320327

TI Agglomerated granular protein-rich nutritional supplement

IN Lockwood, Christopher

PA USA

SO U.S. Pat. Appl. Publ., 16 pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004071825	A1	20040415	US 2002-271239	20021015
	WO 2004034986	A2	20040429	WO 2003-US32646	20031015

WO 2004034986 A3 20050120

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM,  
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,  
TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003287150 A1 20040504 AU 2003-287150 20031015

PRAI US 2002-271239 A 20021015

WO 2003-US32646 W 20031015

L64 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Compositions for potentiating a growth hormone

AB A pharmacol. acceptable growth hormone-potentiating composition for ingestion in a mammal, such as human, in a pill form, is described. The composition comprises (i) a Mucuna pruriens extract, containing at least 20% by volume of L-dopa, an active element in stimulating the release of natural growth hormone, and (ii) a Tribulus terrestris extract, containing a luteinizing agent, e.g., a saponin or alkaloid, which prevents degradation of L-dopa. Absorbed L-dopa crosses the blood-brain barrier where it is then decarboxylated to give a catecholamine (dopamine), a growth hormone releasing factor. The composition further comprises a Muira puama extract, for enhancing a prosexual characteristics, and a horny goat weed extract for dilating blood vessels. The pill has an outer surface covered by a protective coating, e.g., shellac or Et cellulose, which retards acidic degradation of the herbal exts. The combination of herbal exts. and protective coating result in enhanced uptake of L-dopa into the mammalian system.

AN 2002:65983 HCAPLUS <<LOGINID::20070716>>

DN 136:123648

TI Compositions for potentiating a growth hormone

IN Mesko, Charles A.

PA USA

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

PATENT NO.

KIND

DATE

APPLICATION NO.

DATE

PI US 6340474

B1

20020122

US 1999-366454

19990803

PRAI US 1999-366454

19990803

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 167 -17 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:n

=> d 167 1-7 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L67 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Immunoglobulins, growth factors and growth hormone in bovine colostrum and the effects of processing

L67 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effects of feeding colostrum and a formula with nutrient contents as colostrum on metabolic and endocrine traits in neonatal calves

L67 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effects of bovine colostrum truncated insulin-like growth factor-1 on cardiac content of angiotensin II in streptozocin-induced diabetic rats

L67 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effect of bovine colostrum truncated IGF-1 on metabolism and kidney in STZ-induced diabetic rats

L67 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I

L67 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Insulin-like growth factor-I, GH, insulin and glucagon concentrations in bovine colostrum and in plasma of dairy cows and neonatal calves around parturition

L67 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effects of anabolic agents on protein breakdown in L6 myoblasts

=> d l67 1 2 4 6 7 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L67 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Immunoglobulins, growth factors and growth hormone in bovine colostrum and the effects of processing

AB In colostrum collected 0-80 h postpartum the contents of Igs, transforming growth factor beta-2 (TGF- $\beta$ 2), insulin-like growth factor-1 (IGF-1) and growth hormone (GH) were analyzed. Colostrum initially contained 90 mg mL<sup>-1</sup> IgG1, 2.8 mg mL<sup>-1</sup> IgG2, 1.6 mg mL<sup>-1</sup> IgA, 4.5 mg mL<sup>-1</sup> IgM, and these concns. declined by 92%, 87%, 93% and 84%, resp., in the samples collected later. Of the growth factors, colostrum initially contained 289-310 ng mL<sup>-1</sup> TGF- $\beta$ 2 and the concentration diminished to 66 ng mL<sup>-1</sup>. The content of IGF-1 and GH postpartum decreased from 870 to 150 ng mL<sup>-1</sup>, and from 0.17 to <0.03 ng mL<sup>-1</sup>, resp. Heat treatment and freeze-drying of colostrum whey decreased the content of Igs to 75%, while the contents of IGF-1 and TGF- $\beta$ 2 were unaffected. A similar processing, including filtration steps reduced also the IGF-1 and TGF- $\beta$ 2 by 25%. IgM seems to be the most sensitive of the Igs to processing.

AN 2002:893373 HCAPLUS <<LOGINID::20070716>>

DN 138:302870

TI Immunoglobulins, growth factors and growth hormone in bovine colostrum and the effects of processing

AU Elfstrand, Lidia; Lindmark-Mansson, Helena; Paulsson, Marie; Nyberg, Lena; Akesson, Bjorn

CS Department of Food Engineering, Lund University, Lund, SE-221 00, Swed.

SO International Dairy Journal (2002), 12(11), 879-887

CODEN: IDAJE6; ISSN: 0958-6946

PB Elsevier Science B.V

DT Journal

LA English

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN  
 TI Effects of feeding colostrum and a formula with nutrient contents as

colostrum on metabolic and endocrine traits in neonatal calves  
AB Colostrum provides high amts. of nutrients and nonnutrient substances to neonates. To study differences between effects of nutritional and non-nutritional components on growth, health status and metabolic and endocrine traits, a formula was created based on bovine milk components which contained similar amts. of nutrients as bovine colostrum during the first 3 days of lactation, but only trace amts. of growth factors (such as insulin-like growth factor 1) or hormones (such as insulin) in whey. Calves were fed either pooled colostrum of milkings 1 to 6, obtained during the first 3 days of lactation (GrC, n = 7) or a formula in the same amts. as colostrum (GrF, n = 7) for the first 3 days, followed by a milk replacer up to day 7. Pre- and postprandial blood samples were taken on days 1, 2, 3 and 7 for the determination of metabolic

and endocrine traits and on day 5 we measured intestinal absorptive capacity by testing xylose absorption. Plasma concns. of total protein and IgG and  $\gamma$ -glutamyltransferase activity were lower ( $p < 0.05$ ), whereas albumin and urea concns. were higher ( $p < 0.05$ ) in GrF than GrC during the first week of life. Plasma glucose concns. were variably affected. Plasma triglyceride, phospholipid and cholesterol concns. were higher ( $p < 0.05$ ) in GrC than GrF on days 3 and 7. Insulin and growth hormone concns. were higher ( $p < 0.05$ ) in GrC than GrF on days 2 and 3 and on days 1 and 2, resp., and glucagon concns. were higher ( $p < 0.05$ ) in GrC than GrF on day 1 and higher ( $p < 0.05$ ) in GrF than GrC on day 3. Cortisol concns. were higher ( $p < 0.05$ ) on days 2 and 3 in GrF than GrC. Plasma xylose concns. rose more markedly ( $p < 0.05$ ) in GrC than GrF. In conclusion, feeding only trace amts. of bioactive substances appears to impair intestinal absorptive capacity and protein and fat metabolism and exert effects on endocrine systems in neonatal calves.

AN 2000:587811 HCAPLUS <<LOGINID::20070716>>

DN 134:4344

TI Effects of feeding colostrum and a formula with nutrient contents as colostrum on metabolic and endocrine traits in neonatal calves

AU Rauprich, A. B. E.; Hammon, H. M.; Blum, J. W.

CS Division of Nutritional Pathology, Institute of Animal Breeding, University of Berne, Bern, CH-3012, Switz.

SO Biology of the Neonate (2000), 78(1), 53-64  
CODEN: BNEOBV; ISSN: 0006-3126

PB S. Karger AG

DT Journal

LA English

RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L67 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Effect of bovine colostrum truncated IGF-1 on metabolism and kidney in STZ-induced diabetic rats

AB The normal and streptozotocin-induced diabetic rats were fed or injected i.p. with the bovine colostrum truncated insulin-like growth factor-1 (IGF-1) for 32 days. The bovine colostrum truncated IGF-1 had obvious hypoglycemic effect in diabetic rats, but no effect in normal rats. It could decrease serum triglyceride and cholesterol levels in diabetic rats and i.p. administration yield more effect on triglyceride than on cholesterol. The serum IGF-1 enhanced markedly after its administration in diabetic rats and the growth hormone level in the group subjected to i.p. administration and the insulin level in the group subjected to oral administration declined significantly. No pathol. changes of the kidney could be observed in both diabetic and normal rats. The results suggest that the bovine colostrum truncated IGF-1 has potent hypoglycemic and hypolipidic effects, can improve metabolism, and exerts a protective effect on kidney of diabetic rats.

AN 1998:385717 HCAPLUS <<LOGINID::20070716>>

DN 129:159539

TI Effect of bovine colostrum truncated IGF-1 on  
 metabolism and kidney in STZ-induced diabetic rats  
 AU Sun, Kan; Yu, Maohua; Shi, Hongli; Yang, Xiufang; Fang, Jingchong; Zhu,  
 Xixing; Yan, Yiqian; Wang, Xiaofei; Zhong, Cisheng  
 CS Diabetic Research Unit, Huashan Hospital, Shanghai Medical University,  
 Shanghai, 200040, Peop. Rep. China  
 SO Zhonghua Neifenmi Daixie Zazhi (1997), 13(3), 162-166  
 CODEN: ZNDZEK; ISSN: 1000-6699  
 PB Shanghaishi Neifenmi Yanjiuso  
 DT Journal  
 LA Chinese

L67 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Insulin-like growth factor-I, GH, insulin and glucagon concentrations in  
 bovine colostrum and in plasma of dairy cows and  
 neonatal calves around parturition

AB The insulin-like growth factor-I (IGF-I) concns. in colostrum on days 1  
 and 2 after parturition were higher than those in blood plasma of cow or  
 neonate. The modest increase in growth hormone (GH)  
 concns. in cow plasma around parturition would not be enough to stimulate  
 IGF-I release by tissues. The concns. of insulin, GH, and glucagon in  
 colostrum were lower than those in plasma.

AN 1990:70904 HCAPLUS <<LOGINID::20070716>>

DN 112:70904

TI Insulin-like growth factor-I, GH, insulin and glucagon concentrations in  
 bovine colostrum and in plasma of dairy cows and  
 neonatal calves around parturition

AU Oda, Shinnichi; Satoh, Hidetoshi; Sugawara, Tatsuro; Matsunaga,  
 Nobuyoshi; Kuhara, Tetsuya; Katoh, Kazuo; Shoji, Yoshio; Niehei, Akira;  
 Ohta, Minoru; Sasaki, Yasuyuki

CS Fac. Agric., Tohoku Univ., Sendai, 981, Japan

SO Comparative Biochemistry and Physiology, Part A: Molecular & Integrative  
 Physiology (1989), 94A(4), 805-8

CODEN: CBPAB5; ISSN: 0300-9629

DT Journal

LA English

L67 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2007 ACS on STN

TI Effects of anabolic agents on protein breakdown in L6 myoblasts

AB Protein degradation in rat L6 myoblasts was inhibited by high concns. of  
 insulin [9004-10-8] (1  $\mu$ M), fetal bovine serum (0.1-10%), and  
 bovine colostrum (0.1-10%), mixts. rich in growth factor  
 activity. Growth factors achieved maximal effects within 2 h after addition  
 to the cell cultures, but these diminished with time. Protein breakdown  
 was stimulated by dexamethasone [50-02-2] by a process that took several  
 hours to be expressed, but was more pronounced over a 4 h measurement  
 period than over 18 h. The glucocorticoid response was prevented by  
 insulin or cycloheximide. Anabolic agents, e.g., trenbolone  
 [10161-33-8], diethylstilbestrol [56-53-1], and testosterone [58-22-0]  
 did not alter rates of intracellular protein breakdown and did not  
 interfere with the glucocorticoid-induced catabolic response.  
 Anabolic steroids and related agents probably act indirectly on  
 muscle, perhaps by altering concns. of growth factors of the somatomedin  
 type.

AN 1983:533919 HCAPLUS <<LOGINID::20070716>>

DN 99:133919

TI Effects of anabolic agents on protein breakdown in L6 myoblasts

AU Ballard, F. John; Francis, Geoffrey L.

CS Div. Hum. Nutr., CSIRO, Adelaide, 5000, Australia

SO Biochemical Journal (1983), 210(1), 243-9

CODEN: BIJOAK; ISSN: 0306-3275

DT Journal

LA English



=> d his

(FILE 'HOME' ENTERED AT 12:16:05 ON 16 JUL 2007)

FILE 'REGISTRY' ENTERED AT 12:16:14 ON 16 JUL 2007  
L1 1 S MIZOLASTINE/CN

FILE 'STNGUIDE' ENTERED AT 12:16:29 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:19:16 ON 16 JUL 2007

L2 209 S L1  
L3 28832 S (SUSTAINED OR CONRTOLLED OR DELAYED OR SLOW) (W) RELEASE  
L4 145377 S CASTOR OR LECITHIN OR WAX OR (FATTY MATRIX)  
L5 533364 S MALEC OR MALEATE OR TARTARIC OR TARTARATE OR MALIC OR MALATE

FILE 'STNGUIDE' ENTERED AT 12:19:20 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:20:23 ON 16 JUL 2007

L6 47754 S (SUSTAINED OR CONTROLLED OR DELAYED OR SLOW) (W) RELEASE  
L7 8 S L2 AND L6 AND L5  
L8 3 S L7 AND L4

FILE 'STNGUIDE' ENTERED AT 12:20:27 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:20:53 ON 16 JUL 2007  
L9 1 S L7 AND (PY<1999 OR AY<1999 OR PRY<1999)

FILE 'STNGUIDE' ENTERED AT 12:20:56 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:21:03 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:21:04 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:21:32 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:21:32 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:22:06 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:22:06 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:23:23 ON 16 JUL 2007

L10 400 S L6 AND L4 AND L5  
L11 144 S L10 AND (PY<1999 OR AY<1999 OR PRY<1999)

FILE 'STNGUIDE' ENTERED AT 12:23:27 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:23:46 ON 16 JUL 2007

L12 7229 S ANTIHISTAMINE  
L13 0 S L11 AND L12

FILE 'STNGUIDE' ENTERED AT 12:23:49 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:24:14 ON 16 JUL 2007

L14 49959 S TABLET  
L15 47 S L11 AND L14

FILE 'STNGUIDE' ENTERED AT 12:24:17 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 12:24:41 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 12:24:42 ON 16 JUL 2007

L16 FILE 'HCAPLUS' ENTERED AT 12:24:53 ON 16 JUL 2007  
 34 S L15 AND (PY<1997 OR PRY<1997 OR AY<1997)  
 FILE 'STNGUIDE' ENTERED AT 12:24:57 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:25:06 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:25:07 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:27:23 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:27:24 ON 16 JUL 2007  
 L17 FILE 'HCAPLUS' ENTERED AT 12:33:34 ON 16 JUL 2007  
 L18 4 S L2 AND L5 AND L14  
 2713 S (PHARMACEUTICALLY ACCEPTABLE) (W) (EXCIPIENT OR DILUENT OR CARR  
 FILE 'STNGUIDE' ENTERED AT 12:33:37 ON 16 JUL 2007  
 L19 FILE 'HCAPLUS' ENTERED AT 12:34:15 ON 16 JUL 2007  
 255 S L18 AND L5  
 FILE 'STNGUIDE' ENTERED AT 12:34:18 ON 16 JUL 2007  
 L20 FILE 'HCAPLUS' ENTERED AT 12:35:00 ON 16 JUL 2007  
 53 S L19 AND (PY<1996 OR AY<1996 OR PRY<1996)  
 FILE 'STNGUIDE' ENTERED AT 12:35:04 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:35:19 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:35:20 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:37:09 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:37:10 ON 16 JUL 2007  
 FILE 'HCAPLUS' ENTERED AT 12:38:06 ON 16 JUL 2007  
 FILE 'STNGUIDE' ENTERED AT 12:38:07 ON 16 JUL 2007  
 INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE,  
 AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS,  
 CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB,  
 DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 12:54:33 ON 16 JUL 2007  
 SEA MIZOLASTINE (W) (MALEATE OR CITRATE OR TARTRATE OR MALATE OR  
 L21 -----  
 QUE MIZOLASTINE (W) (MALEATE OR CITRATE OR TARTRATE OR MALATE OR  
 -----  
 SEA MIZOLASTINE (W) ?ATE  
 -----  
 0\* FILE ADISCTI  
 SEA L5 (5A) L18  
 -----  
 L22 FILE 'HCAPLUS' ENTERED AT 13:17:19 ON 16 JUL 2007  
 9 S L5 (5A) L18  
 FILE 'STNGUIDE' ENTERED AT 13:17:21 ON 16 JUL 2007  
 L23 FILE 'HCAPLUS' ENTERED AT 13:17:58 ON 16 JUL 2007  
 1 S L22 AND (PY<1997 OR AY<1997 OR PRY<1997)  
 FILE 'STNGUIDE' ENTERED AT 13:18:02 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:18:11 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 13:18:11 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:20:50 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 13:20:52 ON 16 JUL 2007

L24 0 S L5 AND ((ALLREGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT

L25 0 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:08 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:21:20 ON 16 JUL 2007

L26 939 S L5 AND ((ALLREGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT

L27 695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:25 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:21:38 ON 16 JUL 2007

L28 1081 S L5 AND ((ALLERGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANT

L29 695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:21:42 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:22:12 ON 16 JUL 2007

L30 163 S L5 (6A) ((ALLERGIC(W) (RHINOCONJUNCTIVITIS OR RHINITIS)) OR ANTI

L31 695 S L24 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:22:17 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:22:37 ON 16 JUL 2007

L32 103 S L30 AND (PY<1997 OR AY<1997 OR PRY<1997)

FILE 'STNGUIDE' ENTERED AT 13:22:41 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 13:22:54 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 13:22:54 ON 16 JUL 2007

FILE 'REGISTRY' ENTERED AT 14:08:07 ON 16 JUL 2007

EXP L-ARGININE-2-PYRROLIDONE-5-CARBOXYLATE/CN

L33 1 S MALTODEXTRIN/CN

L34 2 S LYSINE/CN

FILE 'STNGUIDE' ENTERED AT 14:09:27 ON 16 JUL 2007

FILE 'REGISTRY' ENTERED AT 14:13:35 ON 16 JUL 2007

EXP ACETYL-L-CARNITINE/CN

L35 1 S E3

FILE 'STNGUIDE' ENTERED AT 14:14:01 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:15:48 ON 16 JUL 2007

L36 2 S L-ARGININE-2-PYRROLIDONE-5-CARBOXYLATE

L37 1041 S L35

L38 55755 S L33 OR L34

L39 1 S L36 AND L37 AND L38

L40 94029 S CORTISOL OR (HUMAN GROWTH HORMONE) OR EXERCISE OR BODYBUILDIN

FILE 'STNGUIDE' ENTERED AT 14:15:54 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:16:06 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:16:07 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:17:07 ON 16 JUL 2007  
L41 1 S L36 AND L37  
L42 75 S L37 AND L40

FILE 'STNGUIDE' ENTERED AT 14:17:10 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:17:36 ON 16 JUL 2007  
L43 54 S L42 AND (PY<2003 OR AY<2003 OR PRY<2003)

FILE 'STNGUIDE' ENTERED AT 14:17:39 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:17:52 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:17:53 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:22:05 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:22:06 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 14:44:20 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 14:44:20 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:13:35 ON 16 JUL 2007  
L44 268 S BEE (W) POLLEN  
L45 15 S COLUSTRUM  
L46 5582 S LYCOPENE  
L47 1 S MACUNA PRURIENS  
L48 433 S GLYCERYLPHOSPHORYLCHOLINE  
L49 57749 S (GROWTH HORMONE) OR ANABOLIC OR BODYBUILDING

FILE 'STNGUIDE' ENTERED AT 15:13:41 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:14:35 ON 16 JUL 2007  
L50 3 S L44 AND L49  
L51 0 S L45 AND L49  
L52 14 S L46 AND L49  
L53 5 S L48 AND L49

FILE 'STNGUIDE' ENTERED AT 15:14:40 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:15:00 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:15:00 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:15:24 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:15:25 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:16:00 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:16:01 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:16:12 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:16:13 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:17:17 ON 16 JUL 2007

FILE 'STNGUIDE' ENTERED AT 15:17:18 ON 16 JUL 2007

FILE 'HCAPLUS' ENTERED AT 15:18:13 ON 16 JUL 2007

L54 4612 S MALTODEXTRIN  
 L55 5 S L53 AND L49  
  
 FILE 'STNGUIDE' ENTERED AT 15:18:32 ON 16 JUL 2007  
  
 FILE 'HCAPLUS' ENTERED AT 15:19:12 ON 16 JUL 2007  
 L56 15 S L54 AND L49  
  
 FILE 'STNGUIDE' ENTERED AT 15:19:14 ON 16 JUL 2007  
  
 FILE 'HCAPLUS' ENTERED AT 15:19:31 ON 16 JUL 2007  
 L57 9 S L56 AND (PY<2003 OR AY<2003 OR PRY<2003)  
  
 FILE 'STNGUIDE' ENTERED AT 15:19:35 ON 16 JUL 2007  
  
 FILE 'HCAPLUS' ENTERED AT 15:19:41 ON 16 JUL 2007  
  
 FILE 'STNGUIDE' ENTERED AT 15:19:41 ON 16 JUL 2007  
  
 FILE 'HCAPLUS' ENTERED AT 15:20:14 ON 16 JUL 2007  
  
 FILE 'STNGUIDE' ENTERED AT 15:20:15 ON 16 JUL 2007  
  
 FILE 'HCAPLUS' ENTERED AT 15:49:59 ON 16 JUL 2007  
 L58 487 S MUCUNA  
 L59 554 S BOVINE COLOSTRUM  
 L60 13977 S 58 AND 49  
 L61 12339 S 59 AND 49  
 L62 1104683 S 60 AND (PY<2004 OR AY<2004 OR PRY<2004)  
 L63 157831 S 61 AND (PY<2004 OR AY<2004 OR PRY<2004)  
  
 FILE 'STNGUIDE' ENTERED AT 15:50:10 ON 16 JUL 2007  
  
 FILE 'HCAPLUS' ENTERED AT 15:50:40 ON 16 JUL 2007  
 L64 3 S L58 AND L49  
 L65 9 S L59 AND L49  
 L66 3 S L64 AND (PY<2004 OR AY<2004 OR PRY<2004)  
 L67 7 S L65 AND (PY<2004 OR AY<2004 OR PRY<2004)  
  
 FILE 'STNGUIDE' ENTERED AT 15:50:49 ON 16 JUL 2007  
  
 FILE 'HCAPLUS' ENTERED AT 15:50:59 ON 16 JUL 2007  
  
 FILE 'STNGUIDE' ENTERED AT 15:51:00 ON 16 JUL 2007  
  
 FILE 'HCAPLUS' ENTERED AT 15:51:41 ON 16 JUL 2007  
  
 FILE 'STNGUIDE' ENTERED AT 15:51:42 ON 16 JUL 2007  
  
 FILE 'HCAPLUS' ENTERED AT 15:52:59 ON 16 JUL 2007  
  
 FILE 'STNGUIDE' ENTERED AT 15:53:00 ON 16 JUL 2007

=> log hold		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.06	443.31
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-56.16

SESSION WILL BE HELD FOR 120 MINUTES  
 STN INTERNATIONAL SESSION SUSPENDED AT 15:53:51 ON 16 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'STNGUIDE' AT 16:58:10 ON 16 JUL 2007  
FILE 'STNGUIDE' ENTERED AT 16:58:10 ON 16 JUL 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.12	443.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-56.16

=> file rehistory

'REHISTORY' IS NOT A VALID FILE NAME  
SESSION CONTINUES IN FILE 'STNGUIDE'

Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

=> file registry

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.12	443.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-56.16

FILE 'REGISTRY' ENTERED AT 16:58:25 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUL 2007 HIGHEST RN 942400-66-0  
DICTIONARY FILE UPDATES: 15 JUL 2007 HIGHEST RN 942400-66-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> exp arginine pyroglutamate/cn

E1	1	ARGININE PROPYL ESTER/CN
E2	1	ARGININE PROPYL ESTER DIHYDROCHLORIDE/CN
E3	2 -->	ARGININE PYROGLUTAMATE/CN
E4	1	ARGININE RACEMASE/CN
E5	1	ARGININE REGULATORY PROTEIN, ARGR, ARAC FAMILY (BURKHOLDERIA XENOVORANS STRAIN LB400)/CN
E6	1	ARGININE REPRESSOR (AEROMONAS HYDROPHILA HYDROPHILA STRAIN A TCC 7966 GENE ARGR)/CN
E7	1	ARGININE REPRESSOR (AEROMONAS HYDROPHILA HYDROPHILA STRAIN A TCC 7966)/CN
E8	1	ARGININE REPRESSOR (ARGININE METABOLISM REGULATOR) (OCEANOBA CILLUS IHEYENSIS STRAIN HTE831 GENE AHRC)/CN
E9	1	ARGININE REPRESSOR (ARTHROBACTER AURESCENS STRAIN TC1 GENE A RGR)/CN
E10	1	ARGININE REPRESSOR (BACILLUS ANTHRACIS STRAIN AMES ANCESTOR A2084 GENE ARGR)/CN
E11	1	ARGININE REPRESSOR (BACILLUS ANTHRACIS STRAIN AMES GENE ARGR)/CN
E12	2	ARGININE REPRESSOR (BACILLUS CEREUS STRAIN ATCC10987 GENE AR GR)/CN

=> sE3

SE3 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.  
For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (=>).

=> s E3

L68 2 "ARGININE PYROGLUTAMATE"/CN

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	5.40	448.77
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-56.16

FILE 'CAPLUS' ENTERED AT 16:58:54 ON 16 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4

FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 168

L69 41 L68

=> file stnguide

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.47

449.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-56.16

FILE 'STNGUIDE' ENTERED AT 16:59:04 ON 16 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> file hcaplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.12

449.36

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-56.16

FILE 'HCAPLUS' ENTERED AT 17:00:12 ON 16 JUL 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2007 VOL 147 ISS 4

FILE LAST UPDATED: 15 Jul 2007 (20070715/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s lysine

L70 108995 LYSINE

=> s 169 and 170

41 L68

L71 11 L69 AND L70

=> s 171 and 149



L72 2 L71 AND L49

=> s l72 and (PY<2004 or AY<2004 or PRY<2004)

23933348 PY<2004  
4729314 AY<2004  
4211172 PRY<2004

L73 2 L72 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	2.60	451.96
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-56.16

FILE 'STNGUIDE' ENTERED AT 17:00:19 ON 16 JUL 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Jul 13, 2007 (20070713/UP).

=> d l73 1-2 ti

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L73 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Nutritional supplement for enhancing the production and effect of natural human growth hormone

L73 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Dietary supplement for promoting healthy hormonal balance

=> d l73 2 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:yy  
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L73 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2007 ACS on STN  
TI Dietary supplement for promoting healthy hormonal balance  
AB A dietary supplement for promoting healthy hormonal balance in adult human subjects, and especially in elderly subjects, comprises a secretagogue for stimulating the release of human growth hormone (hGH) by the pituitary, and the conversion by hGH to insulin-like growth factor 1 (IGF-1), in combination with 7-keto-dehydroepiandrosterone (7-keto DHEA). The dietary supplement also includes other interacting ingredients for delivering antioxidants for retarding damage at the cellular level caused by the presence of free radicals, and natural herbs for promoting physiolo. health. For example, an essentially dry powder constituting a dietary supplement of this invention, to be dissolved in water to provide a daily serving, contained 7-keto-DHEA 25 mg, Symbiotropin 1000 mg, lecithin 200 mg, maltodextrin 7.227 mg, citric acid 640 mg, dipotassium phosphate 25 mg, potassium citrate 25 mg, probiotic blend 100 mg, fruco-oligosaccharides 400 mg, S-adenosyl-L-methionine 5 mg, acetyl-L-carnitine 100 mg, omega-3 fatty acids (Dry n-3) 125 mg, trimethylglycine 100 mg, coenzyme Q10 7.5 mg, resveratrol (Protykin) 10

mg, α-lipoic acid 50 mg, L-glutathione 30 mg, N-acetylcysteine 200 mg, and flavoring agents 300 mg.

AN 2002:271056 HCAPLUS <<LOGINID::20070716>>

DN 136:299719

TI Dietary supplement for promoting healthy hormonal balance

IN Hastings, Carl W.; Barnes, David J.; Daley, Christine A.

PA Reliv' International, Inc., USA

SO U.S., 5 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6368617	B1	20020409	US 2001-858047	20010515 <--
PRAI	US 2001-858047		20010515	<--	

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	460.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-56.94

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 17:00:45 ON 16 JUL 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'STNGUIDE' AT 17:05:39 ON 16 JUL 2007  
FILE 'STNGUIDE' ENTERED AT 17:05:39 ON 16 JUL 2007  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)d

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.06	460.85
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-56.94

=> d 168

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:n


=> d 168 1-2

YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y

L68 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN  
 RN 64855-91-0 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN Proline, 5-oxo-, compd. with L-arginine (1:1) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN DL-Proline, 5-oxo-, compd. with L-arginine (1:1)  
 CN L-Arginine, compd. with 5-oxo-DL-proline (1:1)  
 CN L-Arginine, compd. with 5-oxoproline (1:1) (9CI)  
 OTHER NAMES:  
 CN Arginine pyroglutamate  
 CN Pyroglutargine  
 FS STEREOSEARCH  
 MF C6 H14 N4 O2 . C5 H7 N O3  
 LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAPLUS, CHEMLIST, EMBASE, PHAR,  
 PROMT, PS, TOXCENTER, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: EINECS\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)

CM 1


CRN 149-87-1  
 CMF C5 H7 N O3



CM 2

CRN 74-79-3  
 CMF C6 H14 N4 O2

Absolute stereochemistry.



13 REFERENCES IN FILE CA (1907 TO DATE)  
 2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 13 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L68 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2007 ACS on STN  
 RN 56265-06-6 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN L-Proline, 5-oxo-, compd. with L-arginine (1:1) (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN L-Arginine, compd. with 5-oxo-L-proline (1:1) (9CI)  
 OTHER NAMES:  
 CN Arginine PCA  
 CN Arginine pyroglutamate  
 FS STEREOSEARCH  
 MF C6 H14 N4 O2 . C5 H7 N O3

CI COM  
LC STN Files: BEILSTEIN\*, BIOSIS, CA, CAPLUS, CHEMCATS, CHEMLIST, CSChem,  
DDFU, DRUGU, EMBASE, PHAR, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, USPAT2,  
USPATFULL

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*


(\*\*Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 98-79-3

CMF C5 H7 N O3

Absolute stereochemistry. Rotation (-).




CM 2

CRN 74-79-3

CMF C6 H14 N4 O2

Absolute stereochemistry.



29 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

29 REFERENCES IN FILE CAPLUS (1907 TO DATE)